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1 Introduction 
 
1.1 Cancer and breast cancer 
 
Normal cells can transform into cancer cells due to various cellular deregulations, which 
lead to uncontrolled proliferative growth. The cellular deregulation occurs at various 
levels including genetic, epigenetic, intracellular signaling and microenvironment or 
extracellular interactions [1]. The constant and unpredictable changes in tumor cell 
behavior, especially under treatment stress, increases the complexity of treatment and 
can cause therapy resistance, relapse of tumor, and intra-tumor heterogeneity (ITH). 
Accumulation of different types of gene mutations, translocations and altered gene copy 
numbers lead to deregulation of functional proteins and intracellular signaling cascades. 
In addition, epigenetic alterations such as histone and methylation modifications can 
also company the genetic instability of tumor cells [1, 2]. Compared to normal cells in 
which DNA repair systems will repair DNA damages, deregulation of DNA repair 
mechanisms in cancer cells increases genome instability [1]. Intracellular signaling is 
the network of protein-protein interactions and modifications, which transfer 
environmental stimuli or information into the cells and thus activates or inhibits specific 
cell responses for instance proliferation, differentiation, survival, and apoptosis [1, 3]. 
Compared to normal cells in which cellular signaling is controlled by precise crosstalk 
and feedback systems, in cancer cells the homeostasis of signaling networks is 
disrupted. In this regard, many cancer cells are characterized by over-activation and 
overexpression of some pathways, resulting in uncontrolled responses [1, 4]. Over 
decades, the role of tumor microenvironment (TME) has been highlighted. TME is a 
highly interactive tissue area in which components of the extracellular matrix as well as 
various cell types including tumor cells, fibroblasts, endothelial and immune cells are 
interacting. The bidirectional interaction between tumor cells and microenvironment 
can, thus, promote tumor growth by different ways, for instance releasing cytokines and 
growth factors in TME [1, 5].  
Breast, lung and colon cancer are the three most common cancers worldwide, and breast 
cancer is the most common type in women. Although breast cancer incidents are 
increasing according to the World Health Organization (WHO), mortality from this type 
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of cancer in the European Union (EU) and North America is decreasing [6, 7]. The 
increase in survival is mainly due to early diagnosis and detection of the tumor. In this 
regard, 8% decrease in breast cancer mortality in EU has been reported in 2016 [6]. 
However, breast cancer is still one of the leading life threatening diseases in less 
developed countries. Based on the classification of Perou and coworkers [8], breast 
cancer is divided to four different subtypes including Luminal A, Luminal B, HER2-
enriched and basal like. The differences between these four subtypes can be determined 
based on proliferation marker (Ki67), various receptors such as estrogen receptor (ER), 
HER2 and Progesterone receptor (PgR) [6]. Thus, dependent on the subtype of breast 
cancer, systemic therapy can be guided specifically. The proper therapy plan has to be 
defined based on the stage and subtype of the tumor by a multidisciplinary team. 
Primary surgery is usually the first step in early stage of breast cancer treatment, which 
is followed by either chemo- or radiotherapy. Recently, less invasive radiotherapy 
approaches including partial breast irradiation and hypo-fractionated irradiation has 
been developed [6].   
 
1.2 Radiotherapy  
 
Radiation can be divided into ionizing and non-ionizing radiations. Ionizing radiation 
(IR) refers to high-frequency radiations, which can remove an outer electron from the 
last shell of atom. In this regard, X-rays and gamma rays are counted as ionizing 
radiation [9]. Nonionizing radiation carries lower-frequency energy and only can move 
electrons to a higher energy level without removing them. The nonionizing radiations 
are used routinely such as visible light, radio waves, and microwaves [9]. The radiation 
energy that is deposited in the exposed material (i.e. skin, tumor or organs) is called 
absorbed dose. The absorbed dose, which is measured as gray (Gy) is depend on tissue 
density and depth [9]. One of the most applied features of IR in oncology is the ability 
to damage DNA preferentially in tumor cells. Due to the high proliferation rate of tumor 
cells compared with normal cells, radiation induces more DNA damage in tumor cells, 
which results in stronger sensitivity of these cells to the radiation than in normal cells 
[10]. In this regard, besides surgery radiotherapy (RT) is the most important therapeutic 
option for local tumor treatment. Moreover, compared to other types of cancer therapy, 
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RT has lower costs and currently is used as a common treatment worldwide in which 
approximately 50% of cancer patients undergo RT during their treatment period [10].  
 
1.2.1 Radiotherapy for breast cancer 
 
RT is applied usually as a primary treatment for various type of cancers especially 
breast cancer, which need to be treated before or after chemo-therapy or surgery [10]. 
RT usually applied after removing breast tumor tissue in order to ensure killing of 
remaining tumor cells in the tumor border site to avoid tumor relapse [11]. For several 
years, RT was limited to a fixed conventional protocol in which over 5 weeks the whole 
breast receives fractionated RT with 1.8/2 Gy per fraction. However, nowadays, based 
on new technologies and increased knowledge in the field of radiation biology, new 
protocols and modalities are applied. Hypo-fractionated RT, simultaneous integrated 
boost, intensity modulated RT, volumetric modulated RT, deep-inspiration breath-hold 
are some of the new modalities of RT [11].  
 
1.2.2 DNA double strand break and repair mechanisms 
 
One of the main features of ionizing radiation (IR) is high frequency induction of DNA 
damage. DNA damage occurs due to production of free electrons, which are generated 
by ionizing particles [12]. The accumulation of various ionizations clusters after 
irradiation and additional free radical products from irradiated water molecules 
surrounding DNA leads to structural damage and break in the DNA molecule [12]. 
DNA damage consists of various types of breaks such as single strand breaks (SSB), 
double strand breaks (DSB), base and sugar damages [12]. At the chemical level of a 
DNA strand break, it has been demonstrated that hydrogen abstraction in sugar leads to 
the reaction of neighboring phosphate groups with water and/or oxidation of guanine 
residue which consequently results in a break of the DNA strand [12]. Depending on the 
energy deposit, this leads to either DNA single or double strand breaks. 
Repair of single strand breaks is performed via at least three main mechanisms 
including base excision repair (BER), nucleotide excision repair (NER) and mismatch 
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repair. In BER system, DNA glycosylases provide apurinic or apyrimidinic gaps (AP 
sites) in the sites of single strand damage and then DNA polymerases with AP 
endonucleases synthetize a new DNA single strand based on the non-damaged template 
strand [13]. In addition, NER system usually repairs the massive single strand DNA 
damages via removing 12-24 nucleotides up and down stream of damage site and 
resynthesizes the new DNA strand [13]. The mismatch repair system is directed to the 
mismatched bases after a nick in non-pattern strand. However, the precise mechanism of 
mismatch repair has not been completely understood in mammalian cells [14]. In this 
regard, several models have been proposed such as the stationary, translocation and 
molecular switch models [14]. 
DNA double strand breaks (DNA-DSB) are the most lethal DNA-lesions, which if not 
repaired ultimately lead to cell death [15].  Two main different DNA-DSB repair 
pathways are known, i.e. non-homologous end-joining (NHEJ) and homologous 
recombination (HR) [15]. In comparison to HR, NHEJ is able to perform repair without 
the homologous non-damaged template.  Thus, NHEJ-repaired can be performed by the 
cells independent of the cell cycle phase, whereas HR is only possible in late S and G2 
phase of the cell cycle when the repair system has access to the non-damaged sister 
chromatid as homologous template [15].  
The first step of NHEJ repair is the recognition of DSB and binding of Ku heterodimer 
(Ku70 and Ku80) to the site of break [15, 16]. The high affinity of Ku heterodimers for 
DNA ends is one of the reasons that this heterodimer can recognize DNA-DSB [15].  
Binding of Ku heterodimer together with MRE11-Rad50-NBS1 (MRN) complex 
provides a suitable scaffold for recruiting other proteins involving in NHEJ including 
DNA dependent protein kinase (DNA-PKcs), ataxia telangiectasia mutated (ATM) and 
ataxia telangiectasia and Rad3-related (ATR) [15]. The connection of Ku heterodimer 
and DNA-PKcs leads to the activation of the DNA-PKcs kinase activity. Activation and 
auto-phosphorylation of DNA-PKcs provide the energy and structural shift for DNA 
end processing such as polymerization and ligation [12, 15]. In the last step, the 
XRCC4/Ligase IV complex is recruited to mediate ligation of the DSB [12, 15]. The 
role of chromatin structure during DNA-DSB has been investigated over decades. In 
this regard, Rogakou and coworkers [17] have discovered phosphorylation of a variant 
of histone H2A (H2AX) at serine 139 after ionizing radiation. This study has 
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demonstrated that phosphorylated H2AX (γH2AX) accumulates in foci formed after 
irradiation, which are countable and can, thus, be quantified [17, 18]. Moreover, it has 
been shown that a multi-domain scaffolding protein called MDC1 binds to γH2AX and 
also recruits MRN complex to the site of DNA damage in which it has a crucial role in 
the early step of DNA repair [17, 18].  
 
1.3 Cancer Stem Cells 
 
Genomic diversity of tumors within patients presenting the same type of cancer has 
been known as intra-tumor heterogeneity (ITH) [19]. The degree of genomic diversity 
can range between zero and over eight thousand coding mutations across individual 
tumors [19]. ITH occurs as a result of micro-environmental selection processes and 
mutations, which arise during tumor expansion. Accordingly, ITH reflects cancer cell 
evolution in order to enhance the tumor progression and metastasis [20]. It is also 
evident that ITH is not restricted to genetic abnormalities as it includes as well cell 
surface markers, growth rate and therapeutic response patterns [21, 22]. Tumor 
heterogeneity can change during cancer development as well as in response to the 
treatment regime [22]. Predominantly, phenotype variations in the tumor reflect 
existence of cancer stem cells, which are a result of tumor evolution [21].  
The concept of stemness has been addressed in several studies in the late 1990th by Till 
and McCulloch who identified the self-renewal potential of hematopoietic cells with a 
clonal in vivo repopulation assay [23-25].  Self-renewal is an asymmetric division 
process in which one of daughter cells keep the capacity of stemness and can ensure the 
maintenance of stem cell populations [21]. Although for several decades, the definition 
of stem cells has been only known for normal tissues, in the 1990th Dick and coworkers 
have experimentally developed the concept of tumor-initiating cells [26]. This group 
proved that human acute myeloid leukemia (AML) cells with CD34+ CD38- surface 
marker expression are able to engraft SCID mice and this specific population defines 
the leukemia-initiating cells [26]. Based on this study, the concept of tumor-initiating 
cells or cancer stem cells (CSCs) has been developed for various types solid tumors, 
including breast, brain and colon cancers [21, 22].  By definition, the stemness feature 
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of CSCs refers to self-renewal ability and a variety of cellular functions that enable 
these cells to survive conventional antitumor treatments [21]. As indicated in Table 1.3 
for each type of tumor CSCs are now characterized with specific surface markers.  
 
 
Table 1.3: cancer stem cells surface marker [27] 
 
1.3.1 CD44+/CD24- as CSC markers for Breast cancer 
 
CD44 is a 80- to 95-kDa transmembrane protein, which has a role in cell-cell and cell-
matrix adhesion [28]. One of the major ligand of CD44 is hyaluronan (HA), which 
specially supports stemness of hematopoietic cells. The ubiquitinated form of HA can 
be found in the extracellular matrix in which it supports cell proliferation and migration 
[29]. CD44 can be involved in the intracellular signaling via cytoplasmic tail. In this 
regard, the interaction between CD44 and HA induces of matrix metalloproteinase 9 
(MMP9) activity, which support the metastasis via their accumulation on cell membrane 
[30, 31]. In addition, HA-dependent interaction of CD44 and epidermal growth factor 
receptor (EGFR) is crucial for the cell migration via inducing Akt and Rac1 activity 
[32]. CD44 has not only a functional role but is one of the most prominent markers of 
CSCs. The specific role of CD44 on the expression of putative stem cells markers such 
as Nanog, Oct4 and Sox2 has been shown for several tumor types [33-35]. HA-CD44 
interaction leads to the nuclear translocation of Nanog, Sox2 and Oct4 complex, which 
induce microRNA-302 expression with the final goal of self-renewal and cell survival 
[34]. Activation of PKC via HA-CD44 interaction leads to the phosphorylation of 
Tumor type CSCs specific marker [27] 
Breast  CD24, CD44, ALDH enzyme activity 
Head and Neck CD44, CD271, ALDH enzyme activity 
Colon CD44, CD133, CD166, ALDH enzyme activity 
Lung CD44, CD133, ALDH enzyme activity 
Brain CD133, Nestin 
Liver CD44, CD90, CD133, ALDH enzyme activity 
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Nanog, which induces microRNA-21 production [33]. Moreover, microRNA-21 inhibits 
the tumor suppressor proteins such as PDCD4 and stimulates chemotherapy resistance 
of breast cancer cells [33]. These studies highlight the importance of CD44 in stemness, 
therapy resistance and survival of tumor cells.  
 
1.3.2 Aldehyde Dehydrogenase 1 (ALDH1) as CSC markers for Breast 
cancer 
 
Nineteen different variants of ALDH have been described to date [36]. ALDH isoforms 
are expressed in a variety of tissues and especially in tumor cells [37]. ALDH is an 
enzyme that catalyzes aldehydes to the carboxylic acids. Early studies revealed that 
bone marrow cells with high ALDH activity are prompted stronger to hematopoietic 
progenitor lineage cells and enriched in self-renewal potential [38, 39]. In this line, it 
has been shown that tumor cells with higher ALDH activity are enriched in stem like 
characteristics [37]. In this regard, high ALDH activity level has been demonstrated as a 
potential CSC marker in many types of tumors including breast, lung, colon, prostate, 
brain, and ovary [40]. Various studies on different tumor entities provide evidence that, 
ALDH-positive subpopulations cells are more tumorigenic than the ALDH negative 
cells [41-44]. Moreover, clinically high ALDH activity   is correlated with poor 
prognosis [45-47]. The development of a specific flow cytometric assay 
(ALDEFLUOR), which identifies the activity of ALDH based on fluorescence of the 
substrate (BODIPY-aminoacetaldehyde). In general this specific assay system has 
moved stem cell research forward [48].  
 
1.3.2.1 ALDH and retinoic acid biosynthesis 
 
The isoforms ALDH1A1 and ALDH1A3 are able to convert retinaldehyde to the 
retinoic acid (RA), which regulates the retinoic acid pathway in CSCs [40, 49]. The 
produced RA then binds to the retinoic acid receptor (RAR) and retinoid X receptor 
(RXR), which as heterodimer complex can translocate to the nucleus and regulate the 
expression of more than 500 genes [50]. Based on a negative feedback mechanism this 
heterodimer complex can regulate ALDH expression [51]. As a consequence when the 
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concentration of RA is low, the complex binds to the C/EBPß transcription factor in the 
CCAAT box of the ALDH1 promoter and induces the transcription of ALDH1 gene. 
Conversely, when the concentration of RA is high, C/EBPß make a complex with 
GADD153 in order to block the CCAAT box and to reduce transcription of the ALDH1 
gene [51]. In general, the retinoic pathway is involved in several functional roles in 
tumor cells such as epigenetic modifications, tumor growth and apoptosis [50].  
 
1.3.2.2 Role of ALDH in radio- and chemoresistance 
 
Detoxification is one of the functions of ALDH that can protect cells against harmful 
aldehydes [37]. Analyses of various metabolic syndromes and diseases in which 
different ALDH enzymes are deficient have demonstrated the role of ALDH for the 
detoxification role of ALDH [37]. Moreover, the detoxification aspect of ALDH can 
protect cells to cytotoxic drugs. In this regard, it was first shown that hematopoietic 
cells with high ALDH activity are resistant to the anticancer agents such as 
mafosfamide and oxazaphosphorine [52, 53]. Based on these observations, several 
consecutive studies demonstrated high ALDH activity in various CSCs, which confers 
their resistance to anticancer agents. For example, ALDH-positive populations of 
mantel cell lymphoma (MCL) are resistant to a variety of chemotherapeutic drugs [54].  
On the contrary, inhibition of ALDH activity improves therapy response of high-grade 
ovarian cancer [55]. Moreover, data from over 100 breast cancer patients indicated, that 
ALDH-positivity of tumor cells was related to paclitaxel and epirubicin resistance of the 
corresponding patients [41]. Likewise, it has also been shown that ALDH activity is one 
of the predictors for paclitaxel and epirubicin response in breast cancer patients [56]. 
Regarding the role of ALDH in resistance to radiotherapy, it has been demonstrated that 
subpopulations of HER2+CD44+CD24 tumor cells presenting high ALDH activity are 
radioresistant [57]. Moreover, post-treatment of irradiated breast cancer cells with 
disulfiram, which inhibits ALDH activity, leads to the suppression of stemness gene 
expression and stem like features [58].  
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1.3.2.3 Regulation of ALDH1 activity and gene expression 
 
The responsible molecular mechanisms, which regulate ALDH activity and gene 
expression, are not completely discovered so far. Based on functional characterization 
of ALDH1 promotor, the CCAAT box as the main mediator of ALDH promotor activity 
has been identified in Hep3B cells [59]. It has been shown that the oncogenic subunit of 
mucin 1 (MUC1-C) via ERK signaling can bind to the C/EBPß transcription factor, 
subsequently this complex can bind to the CCAAT box of ALDH1A1 promoter as 
shown for breast cancer cells [60]. Regarding to these findings, a pathway of MUC1-
C/ERK/ C/EBPß regulates ALDH1A1 gene expression in breast cancer cells. Moreover, 
the role of C/EBPß transcription factor has been identified not only on ALDH1A1 gene 
regulation but also on ALDH1A3. It has been shown that C/EBPß in a complex with 
DDIT3 cannot bind to CCAAT box, which leads to a reduction of ALDH1A3 gene 
expression [61]. In this context, it has been demonstrated that inhibition of STAT3-
NFkB activity results in the formation of DDIT- C/EBPß mediates sensitivity of 
ALDH1A3-positive cells to pemetrexed and cisplatin [61]. These findings support the 
prominent role of STAT3-NFkB pathway on ALDH1A3 regulation. Similarly, a 
complex of ß-catenin and T-cell factor (TCF) transcription factors can induce 
radioresistance of prostate cancer cells via direct gene regulation of ALDH1A1 [62]. In 
this study, cells transfected with ß-catenin siRNA were sensitized to ionizing radiation 
[62]. It also has been shown that transforming growth factor ß (TGF-ß) negatively 
regulates transcription of ALDH1A1 gene [63]. The complex of Smad4 and Smad2/3, 
the main mediator of TGF-ß action, can bind to the regulatory region of ALDH1A1 
gene, resulting in reduced proportion of ALDH-positive cells of pancreatic tumor cell 
populations [63].  Moreover, epigenetic regulation of ALDH1A1 by BRD4 proteins, a 
member of BET protein family, which recruits the transcriptional machinery, has been 
recently identified [64, 65]. Importantly, clinical application of a small molecule 
inhibitor of BRD4 successfully suppressed the ALDH1A1 gene expression in ovarian 
cancer cells [65]. In this context it has been shown that treatment with a BRD-4 
inhibitor abrogated the chromatin loop formation between promoter and enhancer of the 
ALDH1A1. This result confirms the importance of BRD4 as a regulatory factor for 
gene expression of ALDH1A1 [65]. In this study, Yokayama and coworkers [65] also 
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provided evidence for the translational potential of BRD4 antagonists as the 
combination of BRD4 inhibitor and cisplatin efficiently improved survival rate of tumor 
bearing mice and suppressed the regrowth of cisplatin-treated tumors in vivo and in 
vitro.  
One of the regulatory mechanisms of ALDH1 expression is posttranslational 
modification. In this regard, the lysine 353 (K353) acetylation site has a regulatory role 
in ALDH1 enzyme activity [66]. Breast cancer cells with reduced levels of ALDH1A1 
acetylation show increased ALDH1 activity, which leads to a improved self-renewal 
capacity [66]. It has been shown that P300/CBP-associated factor (PCAF) as an 
acetyltransferase is responsible for K353 acetylation of ALDH1A1. In contrast, sirtuin 2 
(SIRT2), which as downstream protein of the Notch1 pathway modulates deacetylation 
at K353 of ALDH1A [66]. This result implies that Notch promotes stemness feature of 
breast cancer cells via a SIRT2-dependent deacetylation of ALDH1A1 (Fig.1.5). 
Similarly, the binding of sphingosine-1-phosphate (S1P) to the related receptor (S1PR3) 
induces ALDH-positive populations and thus cancer stem cells (CSCs) in MCF-7 cells 
via ligand-independent Notch1 induction [67].  
 
1.3.3 Nanog as putative stem cell marker 
 
Nanog is one of the transcription factors, which has a crucial role in self-renewal 
capacity of stem cells. In 2003 Nanog has been discovered by Ian Chambers and Kaoru 
Mitsui and coworkers in mouse embryonic cells [68, 69]. Based on their studies, Nanog 
has the potential to maintenance the self-renewal capacity of embryonic cells 
independent of the LIF/Stat3 proteins [69]. The human Nanog gene is located on 
chromosome 12 at 12p13.31 known as Nanog1 [70]. In addition, there are several 
pseudogenes of Nanog, which contain premature stop codons inhibiting transcription 
and translation to the functional protein [71]. There is only one pseudogenes of Nanog, 
NanogP8, which encodes the functional protein with differences in 3 amino acids [72]. 
The 305 amino acids length protein of human Nanog consists of three domains 
including the N-terminus (94 amino acids), homeodomain (60 amino acids) and C-
terminus (151 amino acids) [72, 73]. It has been shown that the C-terminal domain of 
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Nanog contains a tryptophan-rich region, which has a role in homodimerization and 
nuclear export of Nanog protein. The C-terminal subdomain also plays a role in 
transactivation of Oct4 promotor and transcriptional activity of Nanog [73]. In contrast, 
the N-terminal domain has a gene interference role in the transcriptional function of 
Nanog [73]. Moreover, homeodomain of Nanog consists of a region with six amino 
acids (136 YKQVKT 141), which exerts a specific role in nuclear translocation of Nanog 
[73]. It has been demonstrated that Nanog in a complex with other transcription factors 
including Oct4, Sox2 and Lin28 provide the self-renewal capacity of stem cells or can 
reprogram differentiated somatic cells to the stem like state [74]. It has been reported 
that serin 315 phosphorylated P53 can bind to the promoter of Nanog and downregulate 
the gene expression in embryonic cells. In this regard, P53 can suppress the self-renewal 
capacity in order to decrease the genomic instability of cells under DNA damage stress 
[75]. Similarly, the regulatory role of P53 on Nanog has been shown in brain CSCs as 
well [76]. Based on this study, Nanog can promote the stemness feature in P53 deficient 
mouse astrocytes [76]. It has been reported that Gli and GLI family zinc finger 2, as 
downstream component of the Hedgehog pathway can activate the transcription of 
Nanog gene and as a consequence can induce self-renewal of neural stem cells [77]. The 
direct interaction between Nanog and Stat3 has been shown [78, 79]. Based on these 
findings, this complex can translocate to the nucleus and activate production of 
microRNA-21, which results in downregulation of tumor suppressor proteins including 
PDCD4 in head and neck (H&N) squamous carcinoma cells [78]. Moreover, the 
phosphorylated form of Stat3 can bind to the Nanog enhancer region in order to induce 
the expression of Nanog in mouse embryonic cells [79].     
Yet, Nanog does have a role not only in embryonic cells but also in tumor cells. Several 
studies have identified the role of Nanog in CSCs of different types of tumors [80-83]. 
In this regard, it has been shown that NanogP8 similar/comparable to other stem cell 
factors including Oct4 and Sox2 has a direct function in stemness of colorectal cancer 
cells [80]. Moreover, isolated hepatocellular carcinoma cells positive for Nanog, exert a 
stronger ability for self renewal, tumorigenesis as well as resistance to chemotherapeutic 
agents sorafenib and cisplatin [81]. It has also been demonstrated that high expression 
of Nanog together with Oct4 leads to an epithelial-mesenchymal transition, which is 
related to the stemness and tumorigenic potential of lung adenocarcinoma [83]. Based 
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on these studies, Nanog is not only a CSCs marker, which regulates stemness but is also 
involved in various regulatory functions mediating metastasis, proliferation and 
apoptosis [84-86]. In addition, overexpression of Nanog leads to upregulation of ATP-
binding cassette sub-family B member 1 (ABCB1), which is one of the resistance 
strategies of lung adenocarcinoma cells in order to tolerate the chemotherapy including 
cisplatin treatment [83]. Likewise, complex formation of Nanog and Stat3 in breast and 
ovarian cancer cells can activate the expression of multidrug transporter (MDR1) gene, 
which mediates chemoresistance [35].  
1.3.4  Functional assays for cancer stem cells  
 
Several methodologies have been developed over the last years in order to overcome the 
challenges regarding identification, isolation and characterization of CSCs 
subpopulation within a tumor population.  Tumorigenicity of CSCs in immune-deficient 
mice is one of the gold standard functional assay for characterization of CSCs [87].  
Tumor cells that not only have the capacity to initiate a new growing tumor population 
in vivo but are also serially transplantable resemble CSCs. It has been shown that the 
ratio of CSCs in a tumor is less than one into 2500 cells [88]. However, several 
limitations of the in vivo model have been observed including the short life span of 
mice and reversibility of CSCs phenotype in the mouse microenvironment when 
compared to the human situation [87, 88]. The ability of CSCs to form a sphere under 
defined culture conditions is one of the routine in vitro methods to assess the self-
renewal potential [87]. This method has been developed from the neurosphere culture, 
which has been used for maintenance of brain stem cells [87]. For the first time in 2004 
Galli and coworkers could demonstrate self-renewal capacity of glioblastoma cells 
under sphere forming conditions [89]. Various conditions of sphere formation as 
standard methods for CSCs studies have been developed including culture technics in 
low adherent dishes with a covalent hydrogel surface to allow cells grow in sphere not 
in an adherent form. Likewise other culture technologies involve growth factors such as 
epidermal, fibroblast (EGF, FGF) and B27 supplemented medium or culture technics in 
matrigel, which consists of extracellular matrix proteins resembling tumor matrix 
conditions [90]. However, none of these methods do represent so far the in vivo tumor 
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microenvironment, which in several studies has been reported as one of the drawbacks 
of the sphere formation assay [90]. 
1.4 Radio- and chemoresistance of cancer stem cells 
 
Based on various studies [91-93], therapy resistance of CSCs seems to be related to cell 
biological features including low proliferation capacity, adaptation to hypoxic 
conditions, activation of drug efflux systems (i.e. ABC transporters), improved DNA 
repair capacity, epithelial to mesenchymal transition (EMT), and upregulation of several 
survival pathways. As reviewed by Nunes and co workers [91] various signaling 
pathways, which are activated in CSCs of various tumor types like PI3K/Akt and 
NOTCH as well as WNT/β-catenin, Hedgehog and JAK/STAT seem to be involved in 
the regulation of radio- and/or chemoresistance of CSCs.  
 
1.4.1 PI3K/Akt pathway 
 
PI3K/Akt pathway can be activated by a variety of growth factors and cytokines 
including EGFR, VEGFR, PDGFR or Ras and G-protein coupled receptors (GPCRs) 
[94]. PI3K belongs to the family of lipid kinases and phosphorylates the inositol ring of 
phospholipids [94]. The PI3K family has been categorized into four different classes 
named I, II, III, IV [94, 95]. Among these different PI3K classes, it has been 
demonstrated that primarily class I PI3K is involved in growth factor related 
proliferation signaling and tumor growth [94, 95]. PI3K is a heterodimeric protein, 
which consist of regulatory and catalytic subunits named p85 and p110 respectively [94, 
95].  Class I PI3K has been divided to 2 further subclasses including Ia and Ib. Subclass 
Ia is mainly involved in signaling pathway related to the tyrosine kinases and RAS, 
while Ib is involved through GPCRs activation [94, 95]. The regulatory subunit is 
responsible for the connection of the PI3K to the upstream mediators, while the 
catalytic subunit generates the lipid messenger phosphatidylinositol 3,4,5-trsphosphate 
(PIP3) [94, 95]. In this regard, PIP3 plays a role in activation of various proteins that 
have a phenylalanine-tyrosine-valine-glutamate (FYVE) domain, including PDK1 and 
Protein Kinase B (PKB/Akt) [94].  
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Akt, as one of the downstream regulators of the PI3K pathway, consists of three 
isoforms Akt1, Akt2, Akt3. Akt isoforms share 80% similarity in a conserved amino 
acid sequences that include the N-terminal, central kinase and C-terminal domains [96]. 
The three isoforms play different roles in cellular functions. Akt1 is mainly involved in 
cellular growth, while Akt2 has a role in glucose metabolism [96]. The Akt molecule 
contains a specific catalytic domain that can regulate downstream pathways. Several 
phosphorylation sites have been identified on Akt1 including T308 (located in kinase 
domain), S473 (located in C-terminal domain) [97-99]. Moreover, phosphorylation also 
can occur in other Akt isoforms such as in Akt2 (T309 and S474) and Akt3 (T305 and 
S472) [97-99]. PDK1 is the responsible protein for the phosphorylation at T308 site, 
while the mechanistic target of rapamycin complex2 (mTORC2) phosphorylates Akt1 at 
S473 site [97, 100, 101]. Once phosphorylated Akt regulates various downstream 
proteins such as glycogen synthase kinase 3 beta (GSK3ß), forkhead box O 
transcription factor (FOXO), mouse double minute 2 homolog (MDM2), p21, p27 and 
Bcl-2-associated death promoter (BAD) [95]. Akt via regulating the activation of 
downstream proteins plays an important role in cell growth, proliferation and survival 
[95]. It has been reported that Akt via phosphorylation of GSK-3 at serin 21 and serine 
9, which leads to the inactivation of GSK3, plays an important role in cell cycle 
progression and growth in cancer cells.  
More recent studies addressed the role of Akt in DNA-DSB repair pathways such as 
non-homologous end joining and homologous recombination has been demonstrated in 
several studies [96, 102]. In irradiated cells, the C-terminal domain of Akt directly 
interacts with DNA-PKcs, the major enzyme in NHEJ repair, [103-105]. This complex 
stimulates kinase activity of DNA-PKc at the site of DNA damage, which initiates the 
DNA repair processes [96]. Moreover, Akt induces the accumulation of DNA-PKcs 
after irradiation in the nucleus and especially at the DNA-DSB [96]. It also has been 
shown that Akt indirectly via ATM regulates DNA-PKcs [96]. In this regard, Akt1 and 
Akt3 mediate ATM-dependent DNA-PKcs phosphorylation in lung cancer cells and 
glioma cells [96, 102, 106]. Based on these results, activation of upstream proteins of 
Akt such as erbB receptors, PTEN, Ras and PI3K lead to induction of NHEJ DNA 
repair capacity in Akt-dependent manner [96]. In addition, it has been demonstrated that 
activation of Akt leads to MRE11 upregulation and induction of DNA repair [96, 107]. 
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MRE11 compared to DNA-PKcs is involved in the slow component of DNA repair 
[96]. Thus, Akt plays role in both fast and slow component of DNA repair. The role of 
Akt in HR DNA repair pathway has been addressed in several studies presenting 
contradictive results. As demonstrated by Mueck and coworkers, downregulation of 
Akt1 leads to a reduction of Rad51 protein level and foci formation after irradiation 
[108]. However, it has also been shown that Akt does impair the nuclear translocation 
of Chk1 and complex formation of Chk1-Rad51 in Brca1-deficient tumor cells [109]. In 
addition, high activation of Akt by phosphorylation at serine 473 site is related to 
BRCA1 deficiency [110]. 
 
1.4.2 Notch Pathway 
 
Notch receptor as a single-pass transmembrane protein consists of an extracellular and 
intracellular region. The extracellular region of Notch contains a negative regulatory 
domain and a heterodimerization domain. The intracellular region is composed of a 
protein-binding site named RPBJ-associated molecule (RAM) and a transcriptional 
activation domain [111]. In mammals different coding genes give raise to four different 
types of Notch receptors (Notch1-4) [111] and among them, Notch1 and Notch2 are the 
most common Notch receptors, which are expressed in a wide range of tissues. Notch3 
and Notch4 receptors are primarily expressed in vascular smooth muscle and 
endothelium only [111]. Ligand binding to the Notch receptor induces protease activity 
of γ-secretase, which cleavages the receptor and releases Notch intercellular domain 
(NICD), which results in activation of Notch [112]. NICD can translocate to the 
nucleus, which binds to DNA via the RAM domain in order to regulate the 
transcriptional activity of downstream target genes including p21, cyclin D1, c-Myc, 
NF-kB2, ErbB2 and apoptosis regulator genes [111-117]. Upregulation and ligand 
activation of Notch seems to be associated with progression of various tumors via 
overexpression of cyclin D1 [118]. Furthermore, Notch represses expression of cell 
cycle inhibitor proteins such as p27 and p57, which induce cyclin D1 [119]. In this line, 
it has been shown that Notch via direct induction of c-Myc leads to cell proliferation 
[120]. Moreover several studies indicated that Notch via cross talks with other signaling 
pathways including PI3K/Akt, Ras and EGFR73 does activate cell survival and 
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proliferation of tumor cells [121, 122]. In addition, the regulatory function of Notch on 
tumor expression of suppressor genes has also been investigated with respect to the 
downregulation of p53 and PTEN activity, which are involved in apoptosis [121, 123]. 
Moreover, Notch via HIF-1 signaling can lead to VEGF expression, which is a crucial 
protein for blood vessels development in tumors [124]. Several studies have 
demonstrated the role of Notch in chemo- and radioresistance of tumor cells. It has been 
shown that combination therapy with Notch inhibitors increases colon cancer cell 
sensitivity to treatment with oxaliplatin or taxanes [125]. Additionally, it has been 
observed a Notch mediates chemoresistance of tumor cells of ovarian cancer and 
hepatocellular carcinoma to cisplatin and doxorubicin [126, 127]. Likewise, Notch via 
overexpression of survivin leads to the inhibition of apoptosis in breast cancer cells 
[128] and the combination of Notch inhibitor and trastuzumab is able to sensitize 
HER2-positive breast cancer cells [129]. As Notch is one of the major regulators of 
cancer stemness, inhibition of Notch (e.g. by Notch inhibitors GSI or a Notch4 
monoclonal antibody) in combination with gefetinib impairs sphere formation of breast 
CSCs [93]. This study demonstrates the correlation of EGFR and Notch pathway in 
CSCs maintenance. In addition and of special interest for the present study, GSI 
treatment impairs tumor cell radioresistance and Notch knockdown combined with Akt 
inhibitor induced cell death of glioma CSCs[130, 131].  
Figure 1.5 presents a schematic illustration of regulation of ALDH activity and Akt 
signaling and the impact of these processes on resistances mechanisms of tumor cells. 
The question marks illustrate the aspects to be investigated in the present thesis, which 
are defined in the following hypothesis. 
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Fig. 1.5: Summary of function of PI3K/Akt and Notch in the regulating ALDH activity 
and radiation response of CSCs. Notch promotes stemness features via a SIRT2-dependent 
deacetylation of ALDH1A1. PI3K/Akt mediates the regulation of radio- and/or chemoresistance 
of CSCs.  
 
1.5 Hypothesis 
 
Hyperactivation of the PI3K/Akt pathway occurs in many tumor entities presenting 
mutations in epidermal growth factor receptor (EGFR) downstream signaling i.e. as 
phosphatase and tensin homolog (PTEN), PIK3CA and Ras [96]. PI3K/Akt pathway 
activity is involved in majority of hallmarks of cancer including cell proliferation, 
survival and metabolism. In the context of tumorigenesis these functions are well 
described nevertheless, the importance of  PI3K/Akt signaling in radioresistance 
through stimulating DNA-DSB repair predominantly through the NHEJ-mechanism has 
been highlighted [96]. Furthermore, evidence from experimental and clinical studies 
indicates that cancer-initiating cells, or cancer stem cells (CSC), are resistant to 
radiotherapy [91]. Among various CSC markers, the role of ALDH activity has been 
highlighted in the last decades. As reported in different studies [56-58], 
stimulated/increased ALDH activity leads to radioresistance of CSCs in various tumor 
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entities. Likewise, Sirt2-dependent deacetylation of ALDH promotes its enzyme activity 
and stimulates stemness feature of breast cancer cells [66]. Moreover, the enhanced 
CSC phenotype is also described to be associated with the activation of the 
PI3K/Akt/mTOR pathway in radioresistant prostate cancer cells (Fig. 1.5) [92]. 
Specifically, it has been demonstrated that the expression of Akt1 and Akt2 increases 
after irradiation of MCF-7 breast cancer [132]. Thus, it seems that Akt isoforms and 
ALDH activity, through an as of yet unknown mechanism, are involved in 
radioresistance of CSCs. It is assumed that CSCs with high ALDH activity (ALDH-
positive cells) are more radioresistant than tumor bulk cells and that they present 
hyperactivated PI3K/Akt pathway. In this regard, a previous study from our laboratory 
has indicated that a selected radioresistant subpopulation of NSCLC-A549 cells and of 
the breast cancer cell line SKBr3 presenting high level of ALDH1 can be 
radiosensitized by the PI3K inhibitor LY294002 [133]. Furthermore, it has been 
reported that targeting EGFR as the major regulator of PI3K/Akt pathway blocks repair 
of DNA DSB and enhances the radiation response of tumor cells [134]. Thus, based on 
the role of ALDH-positive cells in cancer stemness and the role of Akt isoforms in 
radioresistance, the major focus of this project was the investigation of the function of 
PI3K/Akt signaling in radioresistant ALDH-positive breast cancer cells. Therefore, the 
aim of the thesis was to answerd the following questions:   
I. What is the role of Akt isoforms and ALDH activity in DNA repair and 
radioresistance? 
II. Do Akt isoforms regulate ALDH activity and the expression of CSC 
markers?  
III. What is the function PI3K/Akt pathway and other CSC markers on ALDH 
activity? 
IV. Are Akt and/or other CSC markers critical for radioresistance of ALDH 
positive tumour cells? 
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2 Materials and Methods  
 
2.1 Materials 
2.1.1 Equipments  
The following instruments were used in this study 
 
2.1.2 Chemicals 
 
Chemicals Company 
Acetic acid 
Acrylamide 
Agarose 
APS 
Merk 
Roth 
Sigma-Aldrich 
Aldrich 
Equipment  Company 
Analytical balance  Kern & Sohn 
Binocular 
Cell counting chamber 
Detection machine – western blot 
Drying Incubator 
ELISA-Reader 
Electrophoresis 
Flow cytometer 
Incubator 
Light microscope 
pH-Meter  
Semi-Dry-Blot-System 
Tissue Grinder Comp 
Vortexer  
X-Ray irradiation device 
Carl Zeiss 
Fuchs-Rosenthal - Witeg Labortechnik 
LI-COR 
Heraeus 
Anthos Labtec Instruments 
Hoefer  
BD Bioscience 
Binder, Heraeus 
Leitz 
WTW 
Hoefer 
Thomas Scientific 
UniEquip 
Gulmay 
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β-Mercaptoethanol 
Bromphenol blue 
BSA 
DMSO 
DTT 
EDTA 
Ethanol 
Formaldhyde 
HCL  
NP-40 
Ponceau S 
Sodium dodecylsulfate (SDS) 
Sodium chloride 
TEMED 
Triton X-100 
Tris-base 
Tris-HCL 
Tween 20 
Sigma-Aldrich 
Pharmacia Biotech 
Roth 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Merk 
Merk 
Roth 
Sigma-Aldrich 
Sigma-Aldrich 
Serva 
Merk 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Roth 
 
2.1.3 Other materials: biochemical and kits 
 
Biochemical and kits Company 
ALDEFLUOR assay 
DC protein assay reagents (A, B) 
ECL detection kit 
Nitrocellulose membrane 
Phosphatase inhibitor cocktail 2,3 
Protein standard (ladder) 
Protease inhibitor 
Propidium iodide 
Vectashield Mounting Medium (DAPI) 
Watmann paper  
Cell signaling 
BioRad 
Amersham Pharmacia Biotech 
Roth 
Sigma-Aldrich 
BioRad 
Roche 
Roth 
Vector Laboratories  
Schleicher & Schüll 
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2.1.4 siRNA, Plasmids and Inhibitors  
 
siRNA, Plasmid, 
Inhibitors 
Company Catalog Number 
ALDH1 siRNA 
Akt1 siRNA 
Akt2 siRNA 
Akt3 siRNA 
DEAB 
LY-29004 
MK-2206 
Nanog siRNA 
Notch1 siRNA 
Nanog Plasmid 
Non-targeting siRNA 
Dharmacon 
Dharmacon 
Dharmacon 
Dharmacon 
Sigma-Aldrich 
Calbiochem 
Selleckchem 
Dharmacon 
Dharmacon 
Addgene 
Dharmacon 
L-008722-00-0005 
M-003000-03-0005 
M-003001-02-0005 
M-003002-02-0005 
D86256 
440202-5MG 
S1078 
M-014489-02-0005 
M-007771-02-0005 
#28221 
D-001206-13-05 
 
2.1.5 Cell culture materials and cell lines  
 
Cell culture materials: 
Cell culture materials Company 
1, 2, 5, 10 and 25 mL sterile pipets Costar 
6 wells plates Falcon 
60 and 150 mm tissue culture plates Falcon 
DMEM/RPMI meduim Gibco 
FBS PAN-Biotech / Lot No: P170102 
Four chambers polystyrene culture slide Falcon 
LipofectamineTM 2000 Invitrogen 
Matrigel Corning BD 
Optimem Meduim Gibco 
Penicilin-Streptomycin Gibco 
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T-25 and T-75 tissue culture flasks Falcon 
Trypsin Serva 
 
Cell lines: 
 
2.1.6 Antibodies  
 
Antibodies Company Catalog Number 
Actin 
ALDH1  
Akt1  
Akt2  
Akt3  
Alexa Fluor 488 goat antimouse 
Bmi-1 
GAPDH 
HRP-linked sheep anti mouse 
HRP-linked sheep anti Rabbit 
Sigma-Aldrich 
Cell signaling 
Cell signaling 
Cell signaling 
Cell signaling 
Life technologies 
Cell signaling 
Cell signaling 
GE Healthcare 
GE Healthcare 
A2066 
36671 
2967 
2964 
8018 
A11001 
5856 
2118 
NA931 
NA934 
Cell line Tumor Type AACR Number/Company 
A549 
DU145 
DU145 Nanog1-/- 
 
HBL-100 
HCT116 parental 
HCT116 Akt1-/-  
HCT116 Akt2-/- 
MDA-MB-231 Akt1,2,3 KD 
MCF-7 
NM2C5 
SKBR3 
Lung 
Prostate 
Prostate 
 
Breast 
Colon 
Colon 
Colon 
Breast 
Breast 
Melanoma 
Breast 
CCL-185 
A gift from Prof. Yasufumi 
Kaneda and Prof. Keisuke 
Nimura 
HTB-124 
Horizon Discovery/ HDPAR-007 
Horizon Discovery/ HDRO-004 
Horizon Discovery/ HDRO-005 
A gift from Prof. Manfred Jücker 
HTB-22 
CRL-2918 
HTB-30 
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Lamin A/C 
Nanog  
Notch1  
Oct-4 
P-Akt (S473) 
P-H2AX (S139) 
Sirt-2 
Sox2 
Abcam 
Cell signaling 
Cell signaling 
Cell signaling 
Cell signaling 
Millipore 
Cell signaling 
Cell signaling 
40567 
3580 
3608 
75463 
4060 
05-636 
12672 
4900 
 
2.1.7 Buffers and solutions 
 
Anode buffer 
 
 
 
 
 
Cathode buffer 
 
 
 
 
 
DMEM medium 
 
 
 
 
RPMI meduim 
 
 
 
3.10 g boric acid 
4 ml 10% SDS 
200 ml methanol 
1 l ddH2O 
pH 9.0 
 
3.10 g boric acid 
4 ml 10% SDS 
50 ml methanol 
1 l ddH2O 
pH 9.0 
 
12.04 g DMEM 
3.30 g NaHCO3 
900 ml ddH2O 
pH 7.2 
 
9.38 g RPMI-1640 
1.80 g NaHCO3 
900 ml ddH2O 
pH 7.2 
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Lysis buffer 
 
 
 
 
 
 
 
Lysis buffer Cytoplasmic/Nuclear 
extraction (Buffer A) 
 
 
 
 
Lysis buffer Cytoplasmic/Nuclear  
extraction (Buffer B) 
 
 
  
 
PBS 
 
 
 
 
 
Protein loading buffer 
 
 
 
 
 
3.94 g Tris-HCl 
5.40 g ß-glycerol phosphate 
4.38 g NaCl 
0.09 g Na3VO4 
50 ml glycerol 
5 ml Tween-20 
0.02 g NaF 
500 ml ddH2O / pH 7.5 
300 μl Hepes (1M) 
150 μl KCL (1M) 
30 μl MgCl2 (1M) 
75 μl NP40 (10%) 
14450 ml ddH2O 
 
100 μl Tris-HCl (1M) 
150 μl NaCl (5M) 
50 μl EDTA (100 mM) 
25 μl NP40 (10%) 
4650 ml ddH2O  
 
13.7 mM NaCl 
2.7 mM KCl 
80.9 mM Na2HPO4 
1.5 mM KH2PO4 
pH 7.4 
 
20 ml glycerin 
20 ml 10% SDS 
2.50 mg bromophenol blue 
25 ml stacking gel buffer (4x) 
95 ml ddH2O 
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SDS running buffer (5x) 
 
 
 
 
 
Separation gel buffer (4x) 
 
 
 
 
Stacking gel buffer (4x) 
 
 
 
 
Staining solution 
 
 
 
Stripping buffer 
 
 
 
 
 
TBST 
56.2 μl β-mercaptoethanol per 1000 μl 
 
144.10 g glycin 
30.30 g Tris-base 
10.00 g SDS 
2 liter ddH2O 
pH 8.6 
 
90.85 g Tris-base 
20 ml 10% SDS 
500 ml ddH2O 
pH 8.8 
 
30.30 g Tris-base 
20 ml 10% SDS 
500 ml ddH2O 
pH 6.8 
 
0.50 g crystal violet 
27 ml formaldehyde 
1 liter PBS 
 
4.50 g glycin 
3 ml 10% SDS 
3 ml Tween-20 
300 ml ddH2O 
pH 2.2 
 
3.15 g Tris-HCl 
11.70 g NaCl 
2 ml Tween-20 
2 liter ddH2O 
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pH 7.5 
 
2.2 Methods:  
 
2.2.1 Cell culture 
 
Cell lines: 
In the current thesis, several human breast, colon (HCT116), prostate (DU145) and lung 
(A549) cancer cell lines as well as melanoma (NM2C5) were used. SKBR3, MCF-7, 
MDA-MB-231 and HBL-100 cells are breast cancer cell lines derived from metastatic 
site of mammary gland.  
Culture media: 
Cells were cultured in RPMI (MCF-7, HBL-100, SKBR3, HCT-116) or DMEM (A549, 
MDA-MB-231) supplemented with 10 % fetal bovine serum (FBS, PAN Biotech) and 1 
% penicillin/streptomycin (pen/strep). The cells were incubated in 37 0C / 5% CO2 and 
passaged weekly when the cells reached 80-100 % confluency.  
 
2.2.2 Colony formation assay 
 
In order to determine the post irradiation cell survival in vitro, the ability of single cells 
to form a clone after ionizing radiation were evaluated under 2D culture. In order to 
perform pre-plated colony forming assay, cells were seeded in a very low concentration 
(250-500 cells per 6 well plates) in supplemented medium with 20 % FBS in 6 well 
plates to form single colon. Twenty-four hour after seeding, cells were irradiated (0-4 
Gy). Then the cells were incubated for 10-20 days, depending to the type of cells. In the 
experiments that cells were treated with inhibitors (DEAB or MK-2206), the treatments 
were done 24 hours after seeding cells as single cells and next day of treatment (for 
DEAB treatment) or 2 hours later (for MK-2206 treatment), cells were irradiated. When 
cells formed colonies in the size of 50 cells or bigger in control group (0 Gy), cells were 
washed with PBS and fixed with staining solution containing formaldehyde and crystal 
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violet color. The staining solution was incubated for half an hour on the cells and then 
the color washed out by drowning plates in water. After drying the plates, colonies, 
bigger than 50 cells, were counted per well. Plating efficiency (PE) is calculated based 
on counted colonies divided to the number of seeded cells. The surviving fraction 
curves were obtained by Sigmaplot software.  
 
2.2.3 3D sphere formation assay 
 
In order to assess the stemness feature of cells, the sphere formation ability of cells 
under 3D-culture were applied. 96 well plates were coated with 1 % agarose (50 μl) and 
were cooled down. Suspended cells in a defined concentration were mixed with medium 
and 10% matrigel (5mg/ml) in a total volume of 100 μl per well and splitted on the 
coated wells. Four hours after seeding cell suspensions with matrigel, 100 μl meduin 
were added in order to overlay the 3D-culture. In order to avoid drying of upper 
medium layer, the outer wells were filled with 200 μl PBS.  
In order to find the proper concentration of cells which allows the formation of 
individual spheres without merging with neighboring spheres, different cell numbers 
(500, 1000, 2000, 3000 and 4000 cells per well) were seeded and after 8-20 days the 
concentration with the best platting efficiency has been chosen. Irradiation (0-6 Gy) 24 
hours after seeding the mentioned concentration of cells has been applied. Based on this 
setting, following cell concentrations have been used for further experiments:  
 
Cell line Number per well Incubation days 
MCF-7 4000 12 
MDA-MB-231 2000 9 
SKBR3 4000 20 
 
In order to receive single cell suspensions from spheres formed in matrigel for further 
experiments (i.e. flow cytometery), spheres were incubated in 5mM EDTA/PBS 
solution for 20 min on ice.  Solution was then centrifuged (5 min, 200g, 40C) and the 
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pellet was resuspended in 2 ml trypsin/EDTA for 10 min at 370C on the shaker. In next 
step, the resuspended solution was centrifuged (5 min, 200g, 40C), the supernatant was 
removed and cells were further processed for flow cytometery or western blotting.  
 
2.2.4 ALDEFLUOR Assay 
 
Aldefluor assay is a flow-cytometry-based assay to measure the activity of ALDH 
enzyme. Based on this assay, ALDH enzyme is able to catalyze an artificial ALDH 
substrate called BODIPY-aminoacetaldehyde (BAAA) to its fluorescent product 
(BODIPY-aminoacetate (BAA)), which can be measured by flow cytometry. In 
advance, the mixture of activated Aldefluor reagent and assay buffer in the 
concentration of 0.625 μl/125 μl were prepared and kept on ice. After preparation of cell 
suspensions in concentration of 250000 per FACS tube, cells were washed with PBS 
(one time). The ready mixed buffer of Aldefluor reagent and assay buffer were added on 
the cells (125 μl per FACS tube). Cells were incubated for 40 minutes in 370C 
incubator. After incubation, cells were washed 2 times with assay buffer and then 
mixture of assay buffer and 1 μg/mL propidium iodide (PI) color were added on the 
cells (100 μl per tube). FACS tubes were kept on ice in dark condition. Thereafter, 
fluorescence signal was measured by flow cytometery.   
The negative sample/tube is treated with 40 μM DEAB. In this regard, first DEAB was 
added in an empty tube and the mixture of cells with activated Aldefluor reagent was 
then added to the DEAB. The negative sample was incubated under the same condition 
as the test samples.  
 
Tube  Cell number Activated Aldefluor reagent Assay buffer DEAB 
Negati
ve 
250000 0.625 μl 125 μl 40 μM 
Test 250000 0.625 μl 125 μl --- 
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2.2.5 Flow cytometery / cell sorting 
 
In order to measure fluorescence signal, side and forward scatters (SSC, FSC) of 
unstained cells, based on the size of cells, were adjusted and the first population (P1) 
was gated. The next population, based on negative signal of PI color (less than 103), was 
gated as living cells (P2) after P1. Thereafter, single cells were gated based on the ratio 
of height to area/(width) as P3. In the last step, cells with low FITC signal were gated as 
ALDH negative population and cells with high FITC signal were gated as ALDH 
positive population. In order to identify the low FITC signal parameter, DEAB treated 
cell sample was measured.  
The same strategy of gating was applied for sorting the cells. Since, cells pump out the 
fluorescence signal very fast over 2-3 hours of sorting, cells had to be aliquoted in 
FACS tubes (1 million cells /100 μl) and kept on ice. By this strategy, cells are longer 
on ice and the activity of ABC transporters is reduced. In the next step, in order to avoid 
the influence of loosing fluorescence signal with respect to the purity of sorting, a 
distance between the gating of negative and positive populations was implicated. The 
collection tubes contained sterile RPMI medium supplemented with 10 % FBS and 1 % 
pen/strep. After sorting cells were washed with fresh medium and then seeded for the 
aimed experiments.  
2.2.6 Irradiation of cells 
 
Irradiation was performed by Gulmay RS225 X-ray machine using a 0.5-mm copper 
filter with additional settings of 200 kVp, 15 mA. X-ray irradiation has been performed 
based on following settings:  
 
Gy Time Distance to the source 
1 Gy 1.06 min 50 cm 
2 Gy  2.12 min 50 cm 
3 Gy 3.18 min 50 cm 
4 Gy 4.24 min 50 cm 
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5 Gy 5.30 min 50 cm 
6 Gy 6.36 min 50 cm 
 
2.2.7 siRNA/plasmid transfection 
 
In order to assess the role proteins of interest, the expression of specific proteins was 
either downregulated or upregulated by siRNA/plasmid transfection. Stock 
concentration (20 μM) of siRNA was prepared by adding 250 μl of 1X siRNA buffer to 
5nM siRNA powder. Then the mixture was aliquoted in 20 μl per tube and kept in -
200C freezer. In all experiments, the end concentration of siRNA in which cells were 
treated was 50 nM. Cells were seeded in 6 well plates or 6 cm dishes in a concentration 
that the confluency of cells is around 60-70 % on the following day. For transfection of 
siRNA and plasmids the following mixtures were prepared.  
 
Mix A 6 well plates (µl) 6 cm dishes (µl) 
Optimem 48 120 
Lipofectamin 2 5 
Total Volume 50 125 
 
Mix B1 6 well plates (µl) 6 cm dishes (µl) 
Optimem 47.5 113.75 
Target siRNA 
Nanog/ALDH1/Notch1 
2.5 6.25 
Total Volume 50 125 
 
Mix B2 6 well plates (µl) 6 cm dishes (µl) 
Optimem 47.5 113.75 
Non-target siRNA (Ctrl) 2.5 6.25 
Total Volume 50 125 
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Lipofectamin was incubated for 5 min with optimum (Mix A), the solution was added to 
target and control siRNA mixture (Mix B1 and B2). Then the tubes were incubated for 
20 minutes in room temperature. During the 20 minutes incubation, the previous culture 
medium was changed with fresh medium (without pen/strep). After the incubation the 
mixture of siRNA and lipofectamin was added drop by drop to the cells. The following 
table indicates the required volume of medium and siRNA: 
 6 well plates 6 cm dishes 
Volume of final transfection mixture 100 µl 250 µl 
Volume of fresh medium  900 µl 2250µl 
 
Twenty-four hours after transfection, medium was changed and forty-eight hours after 
transfection cells were used for the aimed experiment, such as colony forming assay, 
Aldefluor assay, residual γH2AX and western blotting. Nanog plasmid (450 ng/µl) 
transfection were performed with the same protocol as for siRNA transfection.  
Cotransfection of Nanog plasmid and Akt/Notch1 siRNA:  
Twenty-four hours after seeding cells, Nanog plasmid was transfected. Twenty-four 
hours after Nanog transfection, Akt/Notch1 siRNA were transfected and next day the 
protein were isolated or cells were used for FACS and colony formation assay. 
2.2.8 Residual γH2AX assay 
 
In order to determine the efficiency of DNA-DSB repair after irradiation, the formation 
of residual γH2AX at the site of break in the nucleus were imaged by 
immunofluorescence staining. Cells were seeded in 4 chamber slides in concentration of 
80000-150000 cells per well depending to the type of cell line. 24 hrs later cells were 
irradiated with 0 and 4 Gy and 24 hours after irradiation cells were fixed with 70 % 
ethanol. For the experiments with Nanog transfected cells, cells were irradiated 24 h 
after transfection and 48 h after irradiation cells were fixed with ethanol.  
Staining fixed cells for residual H2AX: 
Fixed cells were washed two times with cold PBS and then cells were permeabilized for 
10 minutes with 500 µl cold solution of 0.1% Triton/PBS. After permeabilization, cells 
32 
 
were washed with cold PBS and blocked with 3% BSA/PBS solution for 30 minutes. 
After blocking, cells were incubated for one hour with the primary antibody of 
phospho-ser139 H2AX in 1:500 concentration with solution of 1% BSA/PBS. After 
primary antibody incubation, cells were washed three times with cold PBS and then 
incubated for 45 minutes with fluorescence conjugated secondary antibody (anti-mouse) 
in concentration of 1:500 in a dark place. After incubation with secondary antibody, 
cells were washed two times with cold PBS and then a drop of DAPI containing 
solution (Vectashield) was added to the cells. In the last step, cells were covered with a 
glass and kept in dark box under cold temperature (+4o C). Cells were imaged by 
fluorescence microscope in two different colors including Alexa flour 488 (H2AX) and 
DAPI (nucleus).  
 
2.2.9 SDS-PAGE and Western blotting 
 
SDS-PAGE is a conventional technique for the separation of proteins according to their 
molecular weight. Western blotting is a method to define the expression of different 
proteins under various treatment conditions in the cells by specific antibodies. In this 
regard, the differences in the expression of interest proteins were determined after 
applying the treatment such as siRNA or plasmid transfection as well as irradiation. 
Before protein extraction, 5 ml lysis buffer were mixed with 50 µl phosphatase inhibitor 
II, 50 µl of phosphatase inhibitor III, half tablet of protease inhibitors and 5 µl DDT. 
Western blot were done in different steps as described bellow: 
Protein isolation:  
The cells were washed 2 times with cold PBS. The rest of PBS was sucked out 
completely with vacuum. Then the prepared lysis buffer was added on the cells (200µl 
per 6 cm dishes for 70-80% confluent cells, and 350 µl per 6 cm dishes for 90-100% 
confluent cells). Cells were scratched with cell lifter and collected in tubes on ice. In 
next step, cells were sonicated 20 times at low power and centrifuged 15 min, 14000 
rpm, 4°C. Supernatants which has protein extraction were collected.  
Protein concentration measurement:  
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ELISA 96 wells were filled with 5 µl BSA standards (0, 1, 2, 4, 6 and 8 µg) and 5µl of 
extracted proteins (all have to be triplicate) and then 25 µl of buffer A and 200 µl of 
buffer B from protein reagent assay kit were added. After 7 min of incubation, the 
optical density (OD) was measured by ELISA reader. The protein concentration was 
calculated based on standard curve and obtained OD. After finding the concentration of 
proteins, 100 µg protein were mixed with the equal volume of loading buffer and the 
solutions was boiled for 5 minutes at 1000C. After boiling samples were shortly 
centrifuged and loaded on the SDS gel.  
Running and semi dry transferring: 
Samples were run on SDS gels with 72 mA for 2.5 h (for two gels) or with lower mA 
(3-6 mA) overnight. After running SDS gel were covered by nitrocellulose membrane 
and 3layers of whatman paper on each side and anode and cathode buffers were applied. 
Protein transfer was done at 270 mA for 2.5 h. After transferring the membrane was 
stained with ponceau color and then blocked for one hour with 3% milk or BSA 
solution. After blocking the membrane was cut based on the size/molecular weight 
(MW) of the proteins of interest and incubated with the primary antibody overnight. On 
the next day, after three times washing the membrane with TBST, the membrane was 
incubated with horseradish peroxidase (HRP)-secondary antibody for one hour. After 
three times washing with tris-buffered saline (TBST), proteins were detected with ECL 
kit for 10 min. 
 
2.2.10 Subcellular fractionation - Separation of nuclear and 
cytoplasmic proteins  
 
In order to determine the expression of different proteins in the nucleus compared to 
cytoplasmic fraction of cells, subcellular fractions were used. Cells were cultured in 15 
cm dishes. After 7 days, when confluency of cells reached 80-100 %, cells were 
irradiated (4 Gy). Protein isolation was done at different time points after irradiation (30 
min, 1 h, 16 h and 24 h). In specific experiments cells were irradiated 2 h after treatment 
with LY29004, and proteins were isolated 24 h after irradiation. The protein extraction 
and nuclear/cytoplasmic separation has been done based on following description:  
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 Cells were washed 2 times with cold PBS. The rest of PBS was sucked out completely 
with vacuum. 1 ml cold PBS was added to the cells and then cells were scratched with 
cell lifter and collected on ice in tubes. Thereafter, cells were centrifuged for 10 min, 
1100 rpm, 4°C. Supernatants were carefully removed in order to get a proper pellet. The 
pellets were resuspended in 700 µl lysis buffer A and were incubated 10 min on ice. 
After incubation, cell lysates were completely smashed with glass tissue grinder (20 
times). Then, cell lysates were centrifuged for 10 min, 2330 rpm, 4°C. After 
centrifugation, the upper supernatants were collected as cytoplasmic fraction. The 
pellets were washed 3 times with 500 µl lysis buffer A (5min, 2330 rpm, 4°C). After the 
last washing, the supernatants were completely removed in order to have dry pellets. 
The pellets, representing the nuclear fraction, were resuspended in 80-120 µl lysis 
buffer B. Sonication was done only for nuclear fraction as described in the western blot 
section. Thereafter, the nuclear and cytoplasmic fractions were centrifuged and 
supernatants were collected. Protein content was quantified and samples were run on the 
SDS-gels as described in SDS-PAGE and western blot section.  
 
2.2.11 Statistical analysis 
 
Results obtained from colony formation assays, residual γH2AX-foci and ALDH 
activity were tested for statistical significant differences by applying the Student T-Test 
based on the SigmaPlot software version 2001. 
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3 Results 
 
3.1 Expression profile of stem cell markers in breast cancer cell lines 
and role of Akt isoforms on the expression of these marker 
proteins  
 
3.1.1 CSC marker (CSCM) expression in different breast cancer cell 
lines 
 
It is known that the expression of some transcription factors, also called putative stem 
cell markers, is important during the maintenance of a cancer stem cell population. To 
identify potential stem cell levels of different breast cancer cell lines, the protein 
expression of putative stem cell markers including Nanog, Oct4, Sox2, Bmi-1 and 
ALDH1 was evaluated. In this regard, four breast cancer cell lines namely MDA-MB-
231, SKBR3, HBL-100, MCF-7 and in addition the melanoma cell line NM2C5 have 
been investigated. The expression of Oct-4 and Sox2 was more pronounced in SKBR-3, 
compared with the other cell lines (Fig. 3.1). Nanog and ALDH1 were strongly 
expressed in MCF-7. Furthermore, Bmi-1 was strongly expressed in MCF-7 and 
NM2C5. Based on these data, each breast cancer cell line shows a different pattern of 
putative stem cell marker expression indicating the importance of each marker for a 
specific cell line. To determine whether a correlation exists between CSCM expression 
and Akt activity, the phosphorylation level of Akt at serine residue (S473) has been 
analyzed. As it is shown in Fig. 3.1, the ratio of the band intensities of P-Akt to total 
Akt did was strongly elevated in SKBR3 and HBL-100 as compared with MCF-7 and 
NM2C5, whereas for MDA-MB-231 only a faint Akt phosphorylation was to be 
observed. Based on these data, there exists no direct correlation of the expression of 
cancer stem cell markers (CSCM) and Akt expression and its phosphorylation level, 
which is an indicator of its activity.   
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Figure 3.1. CSC marker (CSCM) protein expression level in five different breast cancer 
cell lines. Protein samples from all cell lines were isolated at the same time and conditions 
(confluency state of 80-100%). The expression level of the indicated proteins was analyzed 
using Western blotting. In order to detect proteins with similar molecular weights, after each 
detection the blots were stripped and then incubated with next antibody. The figure illustrates 
one experiment with duplicate cultures.  
 
3.1.2 Effect of Akt isoforms on the expression of CSCM in breast 
cancer cells 
 
The protein Akt is expressed in three different isoforms with different functions. In 
order to identify which isoform plays the main role in stemness and CSCM expression, 
protein analyses of MDA-MB-231 cells with stable knockdown of individual Akt 
isoforms were applied. In order to keep the knockdown level stable, cells were 
constantly cultured under 1.5 µg/ml puromycin treatment. As shown in Fig. 3.2, 
selective knock down of Akt1 resulted in a strong downregulation of the CSCM protein 
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expression such as Nanog and Bmi-1. This data shows that Akt1 expression is necessary 
for the expression of stem cell markers in breast cancer cells.  
 
Figure 3.2. Effect of Akt isoforms on the expression of CSCM in breast cancer cell line 
MDA-MB-231.  Protein samples from parental (control) and Akt1, 2 and 3 shRNA knockdown 
cells were isolated. The expression level of the indicated proteins was analyzed using Western 
blotting. In order to detect the proteins with similar molecular weight, after each detection the 
blots were stripped and then incubated with next antibody. Densitometry values ± SD, represent 
the ratio of the specific protein band intensities to actin. The figure illustrates one experiment 
with triplicate cultures.   
 
3.2 ALDH as a mediator of post irradiation cell survival in breast 
cancer cell lines  
 
3.2.1 Effect of ALDH inhibition by DEAB on post-irradiation cell 
survival 
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ALDH activity has been described to maintain stemness of tumor cells as well as to 
mediate chemo- and radioresistance. Thus, in order to investigate the role of ALDH 
activity on post-irradiation cell survival, different concentrations of DEAB (N,N-
diethylaminobenzaldehyde), a general inhibitor of ALDH activity, were used. To this 
aim, 24 h after seeding different breast cancer cell lines, i.e. MDA-MB-231, SKBR3, 
HBL-100, MCF-7 as well as the lung cancer cell line A549 and the melanoma cell line  
NM2C5 were treated with 0, 20, 40, 60, 80, 100 or 200 µM DEAB for 24 hours. 
Thereafter, cells were either mock irradiated (0 Gy) or irradiated with a single dose of 3 
Gy. After irradiation and depending on the cell line, the used cells were incubated for 10 
to 14 days to allow colony formation. Fig. 3.3 shows the results with respect to the 
surviving fraction of the individual cell lines with and without radiation exposure as 
well as with and without DEAE treatment. According to the cellular radiation response 
profile, the applied cell lines can be classified into the categories radiosentization, 
radioprotection, and no effect. When compared to DEAB-non treated conditions, 
irradiated MDA-MB-231 and SKBR3 cells showed radio-protection after inhibition of 
ALDH (in different concentrations). In contrast ALDH inhibition led to radio-
sensitization of the cell lines HBL-100 and A549. Finally, post-irradiation survival of 
MCF-7 and NM2C5 treated with DEAB was not affected (no effect). Thus, based on 
these results, breast cancer cell lines can be separated into the presented three groups 
showing different radiation responses when ALDH activity is inhibited by DEAB.  
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Figure 3.3. Effect of ALDH inhibition by DEAB on post-irradiation cell survival. Cells 
(confluency state of 80-100%) were seeded in 6 well plates for colony formation assay as 
described in materials and methods. Twenty-four hours after seeding, cells were treated with 
DEAB (0-200 µM) for 24 h followed by irradiation with doses of 0 and 3 Gy. The incubation 
time for different cell lines differed between 10 to 14 days. Survival curves (SF ± SD) were 
calculated based on one experiment with six parallel samples.  
 
High ALDH activity level has been demonstrated as a potential CSC marker in many 
types of cancers. In order to determine the activity of this enzyme, the Aldefluor assay 
has been used. In this regard, to determine the actual activity of ALDH enzyme, cells 
treated with the ALDH-inhibitor DEAB were used as negative control. To define the 
minimum concentration of DEAB that is able to inhibit ALDH activity completely, 
different concentrations of ALDH (0, 15, 20, 40, 60, 80, and 100 µM) were tested in 
two different cell lines originally established from lung (A549) and colon (HCT116) 
carcinoma. Data shown in Fig. 3.4 indicate that 40 µM DEAB is able to completely 
inhibit ALDH activity in two mentioned cell lines. Based on this data for further 
experiments 40 µM of DEAB was constantly used to inhibit ALDH activity of the cell 
lines to be tested. 
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Figure 3.4. Determination of the minimum concentration of DEAB to blocks ALDH1 
activity. For this analysis, A549 and HCT116 cells were used. Cells were treated with ALDH 
substrate BAAA according to the Aldefluor assay protocol (see materials and methods) and 
were incubated for 40 min incubation at 37 degree. A) A fluorescence signal obtained after 
treatment with 0, 15 and 40 µM DEAB in A549 cell line. B) Quantitative presentation of ALDH 
activity in two cell lines analyzed after different concentration of DEAB. Bars represent the 
mean value of ALDH percentage from two independent experiments with duplicate cultures.  
 
3.2.2 Dependency of radiation response to the proportion of ALDH 
positive cells  
 
Based on the results shown in Fig. 3.3 we investigated whether the differential post-
irradiation results of the different breast cancer cell lines are due to off-target effects of 
DEAB. To test this, ALDH expression was downregulated by a specific siRNA 
approach directed against the isoform ALDH1. ALDH1 downregulation was confirmed 
for MCF-7 and HBL-100 using western blot analysis (Fig. 3.5A). However, due to the 
already very low basal expression of ALDH1 in MDA-MB-231 cells, no further 
knockdown effect could be detected in this cell line. In order to test colony formation 
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ability under ALDH-siRNA knockdown, cells were seeded 48 h after ALDH1 siRNA 
transfection for colony formation and irradiated 24 h after seeding with doses of 0, 1, 2, 
3, and 4 Gy. Colony formation data shown in Fig. 3.5B are in line with the previous 
data depicted in Fig. 3.3 based on DEAB treatment. MDA-MB-231 cells presented a 
slight radio-protection effect after ALDH1 knockdown at doses of 3 and 4 Gy, whereas 
HBL-100 showed a slight radio-sensitization at doses of 3 and 4 Gy. MCF-7 cells were 
not affected by this treatment approach. Furthermore, in order to investigate the 
differential post-irradiation response pattern of breast cancer cell lines after ALDH 
inhibition, the cell type specific level of ALDH activity in the three cell lines was 
evaluated. To this aim, the activity level of ALDH was evaluated by the Aldefluor 
assay. The results shown in Fig. 3.5C indicate that for MDA-MB-231 cells no ALDH 
activity could be detected, whereas in the cell line HBL-100 approximately 30 % and in 
cell line MCF-7 less than 10% of the cells presented high ALDH-activity. Based on this 
data, it can be concluded that the ratio of ALDH activity in the cells determines the 
post-radiation behavior of the cells to the inhibition of the enzyme. In other words, cells 
with high ALDH activity (i.e. HBL-100) show stronger radio-sensitization effect to 
ALDH-inhibnition than cells with low ALDH activity (i.e. MCF-7 and MDA-MB-231).  
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Figure 3.5. Relation of ALDH activity level and post irradiation cell survival with and 
without ALDH siRNA knockdown in breast cancer cell lines. A) Western blots data of 
ALDH1 protein expression with and without siRNA knockdown in HBL-100 and MCF-7 cells. 
B) Survival curves of the three irradiated breast cancer cell lines with and without ALDH1 
siRNA knockdown. The incubation time for different cell lines differed between 10-14 days. 
Data points and survival curves (SF ± SD) were calculated based on one experiment with 6 
parallel cultures. C) Cells were incubated with Aldefluor reagent as described in materials and 
methods and ALDH activity was measured by flow cytometry. Gating of the fluorescence signal 
was set after treatment of the cells with 40 µM DEAB as negative control.  
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3.3 Role of Akt isoforms on ALDH activity and post irradiation cell 
survival 
 
3.3.1 Role of different Akt isoforms on ALDH activity 
 
According to the western-blot data presented in Fig. 3.2, the expression of the CSC 
marker proteins Nanog and Bmi-1 seems to be dependent on the Akt1-isoform. Thus, 
the question was addressed whether the additional isoforms Akt2 and Akt3 exert similar 
effects on ALDH activity. To test this, ALDH activity of parental as well as Akt1 and 
Akt2 knockout-HCT116 cells were analyzed with the Aldefluor assay. In order to keep 
the knockout-status stable, cells were cultured in the presence of 0.3 mg/ml gentamicin 
(G418) (Fig. 3.6A). As shown in Fig. 3.6B, knockout of Akt1 and Akt2 resulted in a 
strong reduction of ALDH activity when compared with the parental cells. To confirm 
these results Akt1, Akt 2 and Akt 3 isoforms were downregulated by transfection of 
HCT116 parental cells with Akt-isoform specific siRNAs (Fig. 3.6C). Aldefluor assay 
analyses indicated a significant reduction of ALDH activity in Akt1 and Akt3 
downregulated HCT116 cells (Fig. 3.6D). In order to investigate the role of Akt on 
ALDH activity further the breast cancer cell lines HBL-100 and MCF7 were 
additionally analyzed by the described knockdown approach (Fig. 3.6E, G). 
Knockdown of Akt1 and 2 in HBL-100 cells, exerted also a significant effect on ALDH 
activity (Fig. 3.6F). However, knockdown of Akt1, Akt2 and Akt3 in MCF-7 cells did 
not affect the level of ALDH activity (Fig. 3.6H). Thus, at least for HBL-100 and 
HCT116 cells, these data indicate a distinct role of Akt on ALDH. Moreover, these 
results indicate that ALDH activity in MCF-7 cells is not dependent on Akt expression. 
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Figure 3.6 
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Figure 3.6. Role of different Akt isoforms on ALDH activity. A, C, E, G) Expression level 
of the Akt isoforms in HCT116 Akt1 and 2 knockout cells as well as in cells after siRNA 
knockdown of Akt1, Akt2 and Akt3 in HCT116, HBL-100 and MCF-7 cells were analyzed 
using Western blotting. B, D, F, H) Cells (confluency state of 80-100%) were seeded for 
transfection in 6 well plates as described in materials and methods. Forty-eight hours after 
siRNA transfection, cells were analyzed by Aldefluor assay. Gating of the fluorescence signal 
was set after treatment of the cells with 40 µM DEAB as negative control. Each bare represent 
the mean value of the percentage of ALDH activity ± standard deviations (SD) from three 
independent experiments with three parallel cultures. (* p < 0.05, **p < 0.01, and ***p < 0.001, 
Student’s t-test). These data has been already published in Harati MD, et al. IJMS 2019 [135]. 
 
3.3.2 The role of different Akt isoforms on post-irradiation cell 
survival 
 
3.3.2.1 HBL-100 
 
In several studies, it has been demonstrated that CSCs are chemo- and radioresistance. 
Thus, the determination of the underlying regulatory pathways in CSCs is important. To 
this aim, the role of Akt isoforms and ALDH on post-irradiation cell survival of breast 
cancer cells was investigated. Therefore, colony formation after knockdown of the three 
different Akt isoforms (1, 2 and 3) in HBL-100 cells was analyzed. As shown in Fig. 
3.7A, downregulation of all Akt isoforms led to a significant radiosensitization in HBL-
100 cells; the strongest effect was apparent when Akt3 was knocked down (Fig. 3.7A 
and 3.7C). Moreover, in order to investigate the correlation of Akt and ALDH on post-
irradiation cell survival, siRNA based knock down of Akt1, 2 and 3 was combined with 
a subsequent DEAB (40µM) treatment. Yet, as shown in Fig. 3.7B, DEAB inhibition of 
ALDH and knockdown of the three Akt isoforms did not result in a further 
radiosensitization of HBL-100 cells. So far, these results indicate that Akt in the context 
of radiation sensitivity seems to act upstream of ALDH. Thus, when Akt is 
downregulated inhibition of ALDH does not show any additional effect on post-
irradiation cell survival.  
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Figure 3.7.  Role of different Akt isoforms in combination with DEAB treatment on post-
irradiation cell survival of HBL-100 cells. A) Cells (confluency state of 80-100%) were 
seeded for transfection in 6 well plates as described in materials and methods. Forty-eight hours 
after siRNA directed against Akt isforms (1, 2 and 3), cells were seeded and then 24 h later cells 
were irradiated and incubated for colony formation as described in materials and methods. B) 
siRNA transfected cells were treated with 40 µM DEAB after seeding for colony formation and 
irradiated 24 h later. Survival curves (SF ± SD) were analyzed based on two independent 
experiments with 12 parallel samples. C) Numbers shown indicate the P-values for cell survival 
shown in figure A for specific irradiation and Akt 1, 2 and 3 siRNA curves compared to 
controle siRNA.  
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3.3.2.2 MCF-7 and MDA-MB-231 
 
In order to evaluate the role of Akt isoforms and ALDH on post-irradiation cell survival 
of the other breast cancer cell lines, i.e. MCF-7 and MDA-MB-231, the same 
experimental strategy as addressed before (se Fig. 3.7A and B) has been applied. Thus, 
colony formation ability after knockdown of three different Akt isoforms (1, 2 and 3) 
was analysed. Yet, the results shown in Fig. 3.8A and 3.8C indicate that downregulation 
of all Akt isoforms did not affect the radiation response of MCF-7 as well as MDA-MB-
231 cells. To investigate the potential correlation of Akt and ALDH on post-irradiation 
cell survival further, a combination of Akt siRNA transfection with DEAB (40µM) 
treatment was applied. As shown in Fig. 3.8B, ALDH inhibition in combination with 
knockdown of Akt isoforms did not change the radiation response of MCF-7 cells. 
However, Akt3-knockdown in MDA-MB-231 cells resulted in radio-sensitization (Fig. 
3.8D) indicating the importance of the Akt3 isoform in in the radiation response of this 
cell line. Together, these data show that the role of Akt and ALDH on post-irradiation 
cell survival is dependent on the cell lines and each isoform of Akt has different role in 
the different breast cancer cells.  
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Figure 3.8.  Role of different Akt isoforms in combination with DEAB treatment on post-
irradiation cell survival of MCF-7 and MDA-MB-231 cells. A, C) Cells (confluency state of 
80-100%) were seeded for transfection in 6 well plates as described in materials and methods. 
Forty-eight hours after siRNA directed against Akt isoforms (1, 2 and 3), cells were seeded and 
then 24 h later cells were irradiated and incubated for colony formation as described in materials 
and methods. B, D) siRNA transfected cells were treated with 40 µM DEAB after seeding for 
colony formation and irradiated 24 h later. Survival curves (SF ± SD) were analyzed based on 
two independent experiments with 12 parallel samples. 
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3.4 ALDH activity and radiation response in 3D-culture 
 
3.4.1 Different pattern of sphere formation under 3D-culture 
condition  
 
One characteristic of cancer stem cells is their ability to form spheres. To analyze this 
ability, the breast cancer cell lines used in this study were cultured under 3D condition 
with and without radiation exposure. To this aim, the five different breast cancer cell 
lines were cultured at different cell number concentrations (500 to 4000 cells per well in 
96 well plates) in matrigel as described in the Materials and Methods section. Sphere 
formation of the individual cell lines occurred differentially between day 9 and 20 after 
seeding in matrigel, i.e. 9 days for MDA-MB-231, 12 days for MCF-7 and 20 days for 
SKBR3. Likewise, the morphology of spheres is also dependent on the type of cell line 
used. As shown in the Fig. 3.9A, MCF-7 presented a round morphology, SKBR3 a 
grape shape and MDA-MB-231 stellate morphology. When compared with non-
irradiated cells, the number and size of the spheres of irradiated cells was markedly 
reduced with increasing radiation dose (2, 4 and 6 Gy) (Fig. 3.9B-D).  
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Figure 3.9. Pattern of sphere formation under 3D-culture condition in breast cancer cell 
lines. Cells density of (4000 for MCF-7, SKBR3 and 2000 for MDA-MB-231 per 96 well 
plates) were seeded in to three dimensional culture system using matrigel (0.5 mg/ml) and 
RPMI (for MCF-7 and SKBR3) or DMEM (for MDA-MB-231) with total volume of 200 µl per 
96 well. After 4 h incubation of cells and matrigel in 37 degree, the extra medium (100 µl) has 
been added to each well. A) Morphology of spheres for different cell lines. B-D) Sphere 
formation after irradiation exposure (0, 2, 4 and 6 Gy) of each breast cancer cells was 
determined after 7 to 20 days. The data shown are based on one experiment with four parallel 
cultures for each cell line. 
 
3.4.2 Determination of plating efficacy under 3D-culture  
 
In order to determine the optimal cell number for colony formation under 3D-culture 
condition, the platting efficacy (PE) of the three breast cancer cell lines was analyzed by 
applying different starting cell numbers (500-4000 cells per well). For non-irradiated 
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controls the PE under 3D is about 4% for MCF-7 as well as MDA-MB-231 (Fig. 
3.10A,B) and about 2.5% for SKBR3 (Fig. 3.10C). The optimized seeding density for 
the individual cell lines was determined based on the best PE obtained for each cell line 
under 3D-culture (Fig. 3.10D). Based on these data, it can be concluded that a low 
frequency of CSCs in the total tumor cell population does lead to a lower PE under 3D-
culture condition.   
 
 
Figure 3.10. Plating efficacy under 3D-culture condition (i.e. sphere formation) of breast 
cancer cell lines. A-C) Plating efficacy under 3D-culture. Spheres bigger than 50 cells were 
counted after 7 to 20 days incubation. Plating efficacy was calculated as described in materials 
and methods. D) The table represents the optimized cell number to be seeded for determination 
of sphere formation under 3D-culture condition. Each bare represent the mean value of plating 
efficacy ± standard deviations (SD) from one experiment with four parallel cultures for each 
radiation dose. 
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3.4.3 ALDH activity and CSCM expression under 3D-culture  
 
In order to investigate the expression of CSCM and ALDH activity in formed spheres of 
MCF-7 and MDA-MB-231 cells, Aldefluor assay to determine ALDH activity and the 
protein expression profile of Nanog and ALDH1 was evaluated. Therefore, single cell 
suspension of formed spheres, 12 days after starting the 3D-culture, were prepared and 
analyzed. As shown in Fig. 3.11A and B, cells under 3D-culture condition present 
express a significantly inducted of ALDH activity (83% in MCF-7 and 72% in MDA-
MB-231) when compared with the ALDH activity of cells under 2D-culture condition 
(see Fig. 3.5B). Moreover, as shown in the Fig. 3.11 C, the protein expressions of 
Nanog as well as of the expression of ALDH1 was upregulated under 3D-culture 
condition in 6 Gy irradiated MDA-MB-231 cells when compared to non-irradiated 
control cells. Thus, it can be concluded that the expression of the stem cell markers 
Nanog and ALDH1 is stimulated under/after irradiation.  
Fig .3.11. 
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Figure 3.11. ALDH activity and CSCM expression of the irradiated breast cancer cell lines 
MDA-MB-231 and MCF-7 under 3D-culture. A, B) MCF-7 and MDA-MB-231 cells were 
seeded in matrigel (0.5 mg/ml) and medium with total volume of 200 µl per 96 well. After 12 
days, the spheres formed were brought to the single cell suspensions as described in materials 
and methods. Cells were incubated with Aldefluor reagent as described above and ALDH 
activity has been measured by flow cytometry. Data shown are based on one experiment. C) 
Protein samples were isolated after washing out the matrigel from MDA-MB-231 cells. The 
expression level of the indicated proteins (Nanog and ALDH1) was analyzed using Western 
blotting. Data represent one experiment.  
 
3.5 Radiation response and DNA repair capacity of ALDH-positive 
and negative cells 
 
3.5.1 Profile of protein expression of ALDH positive and negative 
breast cancer cells 
 
In order to investigate the role of ALDH activity in radioresistance further, SKBR3 and 
HBL-100 cells have been sorted for subpopulations presenting high and low ALDH 
activity profiles via FACS applying the Aldefluor assay. Thus, in order to define the 
accurate border of low ALDH activity, DEAB treated (40 µM) SKBR3 and HBL-100 
cells have been recorded as negative control. Moreover, to avoid possible mixture of 
two subpopulations during sorting, a secure gating distance between ALDH-positive 
and -negative populations was applied (Fig. 3.12 A). In order to investigate the 
expression profile of stem cell markers, protein samples were analyzed by SDS-PAGE 
and western blotting as indicated in Fig. 3.12 B. Among the different putative stem cell 
markers analyzed only Nanog and Bmi-1 were markedly overexpressed in ALDH-
positive cells when compared with ALDH-negative cells. Likewise, phosphorylated Akt 
(S473) was upregulated in ALDH-positive cells, indicating an activation of Akt in these 
cells. Moreover, as the Notch pathway plays an important role in CSCs, the expression 
of Notch (NICD) has been specifically investigated in ALDH-positive and ALDH- 
negative cell populations. As demonstrated in Fig. 3.12 B, expression of Notch but not 
of Sirt2 was upregulated in ALDH-positive cells when compared with ALDH-negative 
cells. Furthermore, in order to determine the ALDH isoform responsible for the 
measured ALDH activity, the protein expression profile of ALDH1 and ALDH1A3 was 
determined in ALDH-positive and ALDH-negative cells. As shown in Fig. 3.12 B and 
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C, the expression level of ALDH1A3 but not ALDH1 was upregulated in ALDH-
positive cells when compared to ALDH-negative ones.  Based on these data, it can be 
assumed that the interaction of several proteins including Akt1, Notch1, Nanog and 
Bmi-1 plays an important role in the stimulation/induction of ALDH activity in CSCs.   
 
Figure 3.12. Protein expression profile of ALDH positive and negative cells. A) Strategy of 
separating ALDH-positive and -negative cell populations in FACS. B, C) Expression profile of 
indicated proteins in HBL-100 and SKBR3 cells were analyzed using Western blotting. In order 
to detect the proteins with similar molecular weight, after each detection the blots were stripped 
and then incubated with next antibody. Densitometry values represent the ratio of the specific 
protein band intensity to actin. Data presented are based on two independent experiments for 
each cell line. These data has been already published in Harati MD, et al. IJMS 2019 [135].  
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3.5.2 Comparison of DNA repair capacity of ALDH-positive cells and 
negative cells 
 
It is known that CSCs are characterized by resistance to chemo- and radiotherapy. In 
order to investigate the role of ALDH activity on post-irradiation cell survival, the 
colony formation assays applying for SKBR3 and HBL-100 were performed. Therefore, 
directly after sorting ALDH-positive and ALDH-negative subpopulations, cells were 
seeded into 6 wells plates for colony formation for testing post-radiation cell survival by 
the colony formation ability. Data obtained and presented in Fig. 3.13 indicate a 
significant improved survival of ALDH-positive cells after irradiation when compared 
with ALDH-negative cells. Further, to analyze whether the strong post irradiation 
survival of ALDH-positive cells is related to an improved DNA-DSB repair capacity, 
the analysis of the number of residual-γH2AX foci 24 h post irradiation has been 
performed. As indicated in Fig. 3.13 B, ALDH-positive cells presented a significantly 
lower number of residual γH2AX foci when compared to ALDH-negative cells. These 
data clearly indicate a significantly improved DNA-DSB repair efficacy in ALDH-
positive cells.  
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Figure 3.13. ALDH activity promotes clonogenic cell survival through improved DNA-
DSB repair. A) Colony forming assay of ALDH-positive and –negative SKBR3 and HBL-100 
cells. Sorted cells were seeded for transfection in 6 well plates and then 24 h later cells were 
irradiated and incubated for colony formation as described in materials and methods. The 
incubation time for different cell lines differed between 10 to 14 days. Data points of the 
survival curves represent the mean value of dose dependent of survival fractions ± standard 
deviations (SD) from three independent experiments with 18 parallel samples. B) Residual-
γH2AX foci of ALDH-positive and negative sorted cells. Cells were cultured in chamber slides 
for 2 to 3 days in order to reach the confluency of 60-70%. Twenty-four hours after 4 Gy 
irradiation cells were fixed and later stained for H2AX phosphorylation as described in 
materials and methods. Bars represent the mean value of Residual-γH2AX foci per nucleus ± 
standard deviations (SD) from two independent experiments with at least 100 nuclei per 
condition. (* p < 0.05, **p < 0.01, and ***p < 0.001, Student’s t-test). These data has been 
already published in Harati MD, et al. IJMS 2019 [135]. 
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3.5.3 Role of Nanog in radiation response and ALDH activity  
 
Based on the Nanog protein expression data obtained so far for ALDH-positive and 
ALDH-negative cells (see Fig. 3.12B) as well as for Nanog overexpression in irradiated 
3D-cultured cells (see Fig. 3.11C), the potential role of Nanog in the regulation of 
ALDH activity and radioresistance was investigated. Therefore, Nanog protein was 
either overexpressed or downregulated in HBL-100 and MCF-7 cells (Fig. 3.14A). 
Fourty-eight hours after Nanog- plasmid or Nanog-siRNA transfection, ALDH activity 
was determined based on the described protocol. Compared to control cells Nanog-
overexpressing cells presented a significantly elevated ALDH activity (Fig. 3.14B) 
whereas Nanog-knockdown resulted in significant reduction of ALDH (Fig. 3.14B). 
These data clearly confirm an important role of Nanog in regulating ALDH activity. 
Furthermore, colony formation ability after up and downregulation of Nanog was tested 
for these cells. As shown in Fig. 3.14 C, overexpression of Nanog resulted in a 
significant radioprotective effect and Nanog downregulation by siRNA in a significant 
radiosensitization of HBL-100 and MCF-7 cells. Thus, these data clearly demonstrate 
the role of Nanog on ALDH activity regulation and on post-irradiation cell survival of 
the tested breast cancer cell lines.  
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Figure 3.14. Nanog stimulates ALDH activity and clonogenic cell survival of irradiated 
cells. A) Expression level of Nanog after siRNA mediated knockdown or plasmid 
overexpression in HBL-100 and MCF-7 cells. B) Cells under equal culture condition and 
confluency (80-100%) were seeded for the siRNA and plasmid transfection in 6 wells plates as 
described in materials and methods. Forty-eight hours after Nanog siRNA and plasmid 
transfection, cells were prepared for Aldefluor assay as described before. Bars represent the 
mean value of percentage of ALDH ± standard deviations (SD) from three independent 
experiments with 6 parallel samples. C) Forty-eight hours after Nanog siRNA and plasmid 
based overexpression transfection, cells were seeded for colony formation assay and then 24 h 
later cells were irradiated and incubated for colony formation as described in materials and 
methods. The incubation time for different cell lines differed between 10 to 14 days. Data points 
of the survival curves represent the mean value of dose dependent of survival fractions ± 
standard deviations (SD) from three independent experiments with 12 parallel samples. (* p < 
0.05, **p < 0.01, and ***p < 0.001, Student’s t-test). These data has been already published in 
Harati MD, et al. IJMS 2019 [135]. 
 
3.5.4 Role of Nanog in DNA repair capacity of ALDH-positive cells 
 
In order to investigate specifically the role of Nanog on ALDH mediated 
radioresistance, colony formation ability, i.e. clonogenic activity and the number of 
residual-γH2AX was determined in ALDH-positive cells of the cell lines HBL-100 and 
SKBR3. To this aim, Nanog expression was downregulated by siRNA transfection in 
ALDH-positive HBL-100 and SKBR3 cells (Fig. 3.15A). After irradiation with 4 Gy, 
residual-γH2AX foci were quantified. As demonstrated in Fig. 3.15B, a significant 
increase in residual-γH2AX was apparent after downregulation of Nanog in ALDH 
positive cells when compared with SKBR3 and HBL-100 cells expressing basal level of 
Nanog. Moreover, as shown in the Fig. 3.15B, siRNA mediated downregulation of 
Nanog resulted in a significant radiosensitization of ALDH-positive cells. 
Downregulation of Nanog protein expression in the applied cells was confirmed by 
western-blotting (Fig. 3.5C). For additional control, the effect of Nanog expression on 
DNA-DSB repair of parental non ALDH-sorted HBL-100 and SKBR3 cells was 
determined. As indicated in Fig. 3.15D, in these cells knockdown of Nanog resulted 
only in a slight but non-significant increase of residual-γH2AX foci in non-ALDH-
sorted HBL-100 and SKBR3 cells (Fig. 3.15D). Thus, the results obtained by these 
experiments confirm a specific role of Nanog on DNA-DSB repair capacity of ALDH-
positive cells and cellular radioresistance of the analyzed breast cancer cell lines.  
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Figure 3.15. Role of Nanog in the radiation response of ALDH-positive cells. A) Expression 
level of Nanog protein after siRNA mediated knockdown in ALDH-positive HBL-100 and 
SKBR3 cells was analyzed using Western blotting. B) Residual-γH2AX foci assay ALDH-
positive cells after Nanog downregulation by specific siRNA. Forty-eight hours after Nanog 
siRNA transfection, cells were irradiated with 4 Gy dose. Twenty-four hours after irradiation 
cells were fixed and later stained for H2AX phosphorylation as described in materials and 
methods. Bars represent the mean value of Residual-γH2AX foci per nucleus ± standard 
deviations (SD) from two independent experiments with at least 100 nuclei per condition. C) 
Post irradiation cell survival of ALDH-positive cells with and without Nanog siRNA 
transfection. Forty-eight hours after Nanog siRNA and plasmid based overexpression 
transfection, cells were seeded for colony formation assay and then 24 h later cells were 
irradiated and incubated for colony formation as described in materials and methods. The 
incubation time for different cell lines differed between 10 to 14 days. Data points of the 
survival curves represent the mean value of dose dependent of survival fractions ± standard 
deviations (SD) from three independent experiments with 12 parallel samples. D) Residual-
γH2AX foci in non-sorted cells after Nanog downregulation. Bars represent the mean value of 
γH2AX foci per nucleus ± standard deviations (SD) from one experiment with at least 50 nuclei 
per condition. (* p < 0.05, **p < 0.01, and ***p < 0.001, Student’s t-test). These data has been 
already published in Harati MD, et al. IJMS 2019 [135]. 
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3.6 Subcellular localization of Nanog after irradiation 
 
It is known that Nanog as transcription factor needs to be translocated into the nucleus 
in order to affect gene expressions by binding to the regulatory components of genes 
involved in self-renewal. To analyze this in the context of present study, translocation of 
Nanog to the nucleus was analyzed in the context of exposure of radiation exposure of 
the cells used for this analysis. Therefore, subcellular fractions of mock-irradiated and 
irradiated (4Gy) MCF-7 cells were performed. The nuclear and cytoplasmic proteins at 
different time intervals after radiation exposure (30 min, 60 min, 16 h, 24 h) were 
analyzed by SDS-PAGE and western blotting. As demonstrated in Fig. 3.16, starting at 
30 min post irradiation, a time dependent decrease of Nanog in the cytoplasmic fraction 
was to be observed. Likewise, a time dependent increase of Nanog in the nucleus 
fraction was apparent after irradiation, starting at about 1 hr post irradiation. Thus, these 
results indicate an irradiation induced nuclear translocation of Nanog, which is a 
prerequisite for its function as a transcription factor.    
 
Figure 3.16. Effect of irradiation on nuclear translocation of Nanog. Expression profile of 
cytoplasmic and nuclear Nanog after radiation exposure. Lamin A/C as a nuclear marker and 
Tubulin as cytoplasmic marker was used to proof the purity of subcellular fractionation. 
Densitometry values represent the ratio of specific protein bands intensity to related Lamin A/C 
and Tubulin. Data are based on two independent experiments. 
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As it is known that EGFR signaling stimulates cell survival and DNA repair capacity in 
tumor cells and in order to confirm the data demonstrated in Fig. 3.16, nuclear 
translocation of Nanog under EGF treatment was additionally investigated. Therefor, 
MCF-7 cells were treated with EGF (100 ng/ml) and subcellular fractionation was 
performed at different time points after EGF-treatment (30 min, 60 min, 16 h, 24 h). As 
shown in the Fig. 3.17, the level of cytoplasmic Nanog protein decreased and nuclear 
Nanog protein level strongly increased in a time dependent manner after EFG treatment   
Figure 3.17. Nanog translocates to the nucleus under EGF treatment. Expression profile of 
cytoplasmic and nuclear Nanog after EGF treatment. Lamin A/C as a nuclear marker and 
Tubulin as cytoplasmic marker was used to proof the purity of subcellular fractionation. 
Densitometry values represent the ratio of specific protein bands intensity to related Lamin A/C 
and Tubulin. Data represent one experiment. 
 
These nuclear translocation data of Nanog after irradiation and EGF indicate an 
important role of Nanog on gene regulation in the context of post-irradiation cell 
survival. Therefore, it can be proposed that targeting or inhibiting Nanog´s nuclear 
translocation may sensitize tumor cells to ionizing radiation. Thus, it was tested whether 
targeting/inhibiting PI3K/Akt signaling can modify nuclear translocation of Nanog in 
MCF-7 cells. To this aim, cells were treated with the PI3K inhibitor LY294002 for two 
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hours and subsequently mock irradiated or irradiated with 4 Gy. Twenty-four hours later 
subcellular fractionation was performed to separate nucleus and cytoplasmic fractions. 
As demonstrated in Fig. 3.18 in control cells treated with the solvent DMSO the level of 
cytoplasmic Nanog was markedly decreased and the level of nuclear Nanog was 
markedly increased 24 hrs after radiation exposure. Yet, post irradiation nuclear 
translocation of Nanog was markedly reduced when cells were treated with LY294002, 
which also inhibited radiation-induced phosphorylation of Akt at serine 473. This data 
clearly indicate that nuclear translocation Nanog in irradiated cells is abrogated by 
inhibition of PI3K/Akt pathway.  
 
Figure 3.18. Nuclear translocation of Nanog after irradiation is regulated by PI3K/Akt 
pathway. Protein samples were isolated 24 h after irradiation and 26 h after LY294002 
treatment (5 µM). Protein expression was analyzed by Western blotting. Lamin A/C as a nuclear 
marker and Tubulin as cytoplasmic marker was used to proof the purity of subcellular 
fractionation. Densitometry values represent the ratio of specific protein bands intensity to 
related Lamin A/C and Tubulin. Data are based on two independent experiments. 
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3.7 Functional effect of Nanog via Akt/Notch proteins 
 
3.7.1 Correlation of Nanog expression on expression profile of Akt 
and Notch protein  
 
Based on the data demonstrated so far and indicating stimulated Nanog, P-Akt and 
Notch1 expression levels in ALDH-positive versus to ALDH-negative cells (see again 
Fig. 3.12B), the potential correlation and or interaction of these signaling proteins has 
been investigated. Therefore, protein expression of Akt1 and Notch1 after 
overexpression or downregulation of Nanog has been evaluated in SKBR3, HBL-100 
and MCF-7 cells. In all three cell lines plasmid mediated overexpression of Nanog did 
result in an upregulation of Notch1 protein expression and stimulated phosphorylation 
of Akt at serine 473, but it did not upregulate protein expression of Akt1 and Sirt2 (Fig. 
3.19A). Furthermore, siRNA mediated downregulation of Nanog resulted in a decreased 
Notch1protein expression and reduced phosphorylation of Akt at serine 473 but again 
Sirt2 and Akt1 protein expression was not affected (Fig. 3.19B). These data imply that 
Nanog is able to control cellular radiation response patterns via modulating Akt- and 
Notch-dependent pathways.  
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Figure 3.19. Correlation of Nanog with Akt and Notch protein expression. A) Protein 
expression profile after plasmid based Nanog overexpression in SKBR3, HBL-100 and MCF-7 
cell line. B) Protein expression profile after Nanog downregulation by specific siRNA. A, B) 
The expression level of the indicated proteins was analyzed using Western blotting. In order to 
detect the proteins with similar molecular weight, after each detection the blots were stripped 
and then incubated with next antibody. The data represent one experiment (MCF-7, SKBR3 and 
HBL-100). These data has been already published in Harati MD, et al. IJMS 2019 [135]. 
 
3.7.2 ALDH activity regulated by Nanog depends on expression of 
Notch and Akt activity  
 
As it has been demonstrated above, Nanog can regulate the activation/phosphorylation 
of Akt1 and stimulate the protein expression of Notch1 (see Fig. 3.19), Thus, it has been 
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questioned further, whether Nanog is able to regulate ALDH activity via Akt and 
Notch1 signaling. To answer this question, Nanog was overexpressed in HBL-100 and 
MCF-7 cells and subsequently cells were transfected with Notch1 siRNA to 
downregulate Notch1 expression. Thereafter, ALDH activity was measured while 
Nanog is overexpressed and Notch1 is downregulated. Under this condition, Nanog was 
not able to stimulate ALDH activity (Fig. 3.20A). Furthermore, after Nanog 
overexpression cells were treated with the Akt inhibitor MK2206. As a consequence the 
stimulatory effect of Nanog overexpression on ALDH activity was blocked when Akt-
kinase activity was blocked by MK2206 (Fig. 3.20B). These results indicate that Nanog 
cannot induce ALDH activity when Akt activity is blocked. Consequently it can be 
concluded that Nanog is able to regulate ALDH activity only in the presence of a 
functioning signaling activity via Akt and Notch.  
 
Figure 3.20. Stimulation of ALDH activity by Nanog depends on Notch1 and Akt protein. 
A) ALDH activity has been measured 48 h after Nanog overexpression and 24 h after Notch1 
downregulation. B) ALDH activity has been measured 48 h after Nanog overexpression and 2 h 
after MK2206 treatment (250 nM and 1 µM respectively for MCF-7 and HBL-100). A, B) Cells 
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were incubated with Aldefluor reagent as described in materials and methods. Bars represent the 
mean values of ALDH percentage ± standard deviations (SD) from three independent 
experiments for MCF-7 with 2 parallel samples each and one experiment for HBL-100 with 3 
parallel samples. (* p < 0.05, **p < 0.01, and ***p < 0.001, Student’s t-test).  These data has 
been already published in Harati MD, et al. IJMS 2019 [135]. 
 
3.7.3 Radiaoprotective effect of Nanog depends on expression of Notch 
and Akt1 activity  
 
Based on the results described above, it was further investigated whether the suggested 
correlation/interaction of Nanog, Akt1 and Notch1 is active in modifying the radiation 
response of tumor cells. To test this, Nanog was overexpressed in HBL-100 and MCF-7 
cells and subsequently cells were transfected with either Notch1 or Akt1 siRNA. 
Colony formation assays were performed to analyze the response pattern of these cells 
to radiation exposure. The obtained clonogenic survival data indicated that Nanog 
overexpression does result in radioprotection. However, this effect was not apparent 
when Akt1 and Notch1 were downregulated (Fig. 3.21). In MCF-7 control cells, neither 
Akt1 nor Notch1 knockdown induced radiosensitization (Fig. 3.21). However, siRNA 
downregulation of Akt1 and Notch1 in Nanog overexpressing cells did result in 
radiosensitization of MCF-7 as well as HBL-100 cells. These data have further been 
confirmed by applying Akt inhibition by MK2206 treatment. As demonstrated in the 
Fig. 3.22, the radioprotective effect of Nanog is significantly abrogated by inhibition of 
Akt activity. Thus, these data again confirm a role of Nanog via Akt1 and Notch1 
signaling in triggering the cellular radiation response.  
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Figure 3.21. Nanog Promotes post-irradiation cell survival via Akt1 and Notch1. The 
colony formation assay has been done 48 h after control and Nanog plasmid overexpression and 
24 h after Notch1 and Akt1 downregulation. MCF-7 (A) and HBL-100 (B) cells were seeded in 
6 wells plates and after 24 h they were irradiated (0-4 Gy). Data points of the survival curves 
represent the mean value of dose dependent of survival fractions ± standard deviations (SD) 
from two independent experiments for MCF-7 with 6 parallel samples each and one experiment 
for HBL-100 with 6 parallel samples per condition. (* p < 0.05, **p < 0.01, and ***p < 0.001, 
Student’s t-test). These data has been already published in Harati MD, et al. IJMS 2019 [135]. 
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Figure 3.22. Nanog promotes post-irradiation cell survival via Akt1 and Notch1. A1, A2) 
Cell were seeded for colony formation assay 48 h after Nanog overexpression. Then 22 h after 
seeding, cells were treated with MK2206 and 2 h later (24 h after seeding) were irradiated (0-4 
Gy). Data points of the survival curves represent the mean value of dose dependent of survival 
fractions ± standard deviations (SD) from two independent experiments for MCF-7 with 6 
parallel samples each and one experiment for HBL-100 with 6 parallel samples per condition. 
B1, B2) Protein expression profile after plasmid based Nanog overexpression and MK2206 
treatment in HBL-100 and MCF-7 cell line. (* p < 0.05, **p < 0.01, and ***p < 0.001, 
Student’s t-test). These data has been already published in Harati MD, et al. IJMS 2019 [135]. 
 
 
 
69 
 
3.7.4 Regulatory effect of Nanog on Notch1 and Akt1  
 
In the next experimental approach using the same design, the actual order of Akt and 
Notch protein within Nanog regulatory pathway was addressed. As shown for two cell 
lines MCF-7 and HBL-100 in Fig. 3.23, downregulation of Akt did not affect the 
expression level of Notch1 in both control and Nanog plasmid overexpressing cells. 
However, downregulation of Notch1 markedly reduced the expression level of total Akt 
in control and even stronger in Nanog overexpressing cells (Fig. 3.23). These data 
confirmed the previous finding that Nanog overexpression can is able to stimulate 
Notch1expression and Akt activity. This result also supports the assumption that the 
function of both Nanog and Notch1 is upstream of Akt. 
 
Figure 3.23. Regulatory effect of Nanog on Notch1 and Akt. A, B) Protein samples were 
isolated 48 h after Nanog overexpression and 24 h after Notch1 and Akt1 downregulation. 
Protein expression level of the indicated proteins was analyzed using Western blotting. In order 
to detect the proteins with similar molecular weight, after each detection the blots were stripped 
and then incubated with next antibody. Densitometry values represent the ratio of the specific 
protein band intensity to actin. These data has been already published in Harati MD, et al. IJMS 
2019 [135]. 
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3.8 Knock-out of Nanog impairs post irradiation cell survival and 
DNA-DSB repair  
 
In order to confirm the obtained results regarding the role of Nanog in post 
irradiation response (see Fig. 3.14, 3.15 and 3.19), the prostate cancer cell line 
DU145 knocked out for Nanog (DU145 Nanog-KO) cell line was used. Colony 
formation assays under 2D- and 3D-culture conditions were performed to analyze 
the response pattern of DU145-Nanog knock out and parental DU145 cells to 
radiation exposure. As demonstrated in Fig. 3.24 A, B Nanog knockout significantly 
radiosensitized DU145 cells both under 2D- and 3D-culture conditions when 
compared to parental DU145 controls (Fig. 3.24 A, B). Likewise, a significant 
increase in residual-γH2AX foci was apparent in Nanog knock out cells (Fig. 3.24 
C) indicating a significantly impaired DNA-DSB repair efficacy. Additionally, the 
role of Nanog on stemness was determined by culturing Nanog knock out and 
parental cells under 3D-culture condition. As demonstrated in Fig. 3.24 D sphere 
formation of DU145-Nanog knock out cells was markedly reduced compared with 
parental control cells (Fig. 3.24 D). Moreover, both in Nanog knock out and in 
parental cells it was determined whether Nanog-knock out does affect protein 
expression of Notch1, Bmi1, and Akt1 as well as the phosphorylation status of Akt 
at serine 473. As demonstrated in Fig. 324E Nanog knock out resulted in decreased 
protein expression of Notch1 and Bmi1 but neither Akt1 expression nor Akt 
phosphorylation at serine 473 protein expression was affected. Potentially, this 
effect might be due to a reactivation of Akt as a compensatory behavior of cells 
under long-term Nanog knock out condition. Nevertheless, together these results 
clearly confirmed the importance of Nanog on post-irradiation survival and DNA-
DSB repair capacity of the tested tumor cells.   
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Figure 3.24. Post irradiation cell survival and DNA-DSB repair ability of Nanog knock-out 
cells. A, B) Colony formation assay of Nanog knock out and parental DU145 cells in 2D- and 
3D-culture. Cells were cultured in 6 wells plates (2D-culture) and in matrigel in 96 wells plate 
(3D-culture) based on mentioned protocol in Materials and Methods section. Twenty-four hours 
later single cells were irradiated (0-4 Gy) and cells were incubated for 8 days under 3D-culture 
and 14 days under 2D-culture in order to form colonies/spheres. Data points of the survival 
curves represent the mean value of dose dependent of survival fractions ± standard deviations 
(SD) from two independent experiments with 6 parallel samples each. C) Residual-γH2AX foci 
of Nanog knock out and parental cells. Twenty-four hours after 4 Gy irradiation cells were fixed 
and later stained for H2AX phosphorylation as described in materials and methods. Bars 
represent the mean value of Residual-γH2AX foci per nucleus ± standard deviations (SD) from 
two independent experiments with at least 100 nuclei per condition. D) Sphere formation under 
3D-culture. E) Protein expression level of the indicated proteins was analyzed using Western 
blotting. In order to detect the proteins with similar molecular weight, after each detection the 
blots were stripped and then incubated with next antibody. Densitometry values represent the 
ratio of the specific protein band intensity to actin. (**p < 0.01, and ***p < 0.001, Student’s t-
test). 
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4 Discussion  
 
Therapy resistance is still one of the most important issues and problems in cancer 
treatment. Cancer stem cells (CSCs) represent a small subpopulation within tumor 
tissues mainly represented by so-called tumor bulk cells [21, 22]. CSCs in contrast to 
tumor bulk cells can tolerate and survive conventional chemo- as well as radiation 
therapy protocols [136]. Especially via upregulation of various survival pathways such 
as PI3K/Akt signaling CSCs can overcome treatment effects [91, 92]. Based on insights 
that therapy resistance of solid tumors is mainly due to the presence of CSCs many 
basic as well as translational research activities have been started within the last 5-10 
years [137]. Although radiation therapy in combination with surgery is one of the 
primary treatment options for breast cancer patients, radioresistance of CSCs is still a 
major issue for treatment success. To further improve treatment outcome, it is desirable 
to enhance radiotherapy via targeting resistance mechanism of CSCs to radiation. To 
this aim, and although the basic mechanisms are still not fully understood, targeting 
strategies directed against molecular pathways in CSCs including ALDH activity and 
PI3K/Akt pathway may have a strong potential towards improved therapy outcome 
[137].  
 
4.1 Expression of CSC markers in different breast cancer cell lines in 
vitro 
  
The differential expression of CSCMs in various types of tumors has been shown in 
several studies [138-140]. It has been confirmed that putative stem cell markers such as 
Nanog, Oct4 and Sox2 are not expressed at the same level between different breast 
cancer cell lines such as MCF-7, MDA-MB-231 and T-47D [138]. Based on this study, 
Nanog is mainly expressed in MCF-7 but not in the two other cell lines and Sox2 is 
expressed strongly in T-47D [138]. Data of the present study confirmed the variety of 
expression of putative stem cell markers in the different breast tumor cell lines used. 
These data indicated that each CSC marker might play a specific role in the behavior 
and radiation response of each cancer cell line. It has been described that variations in 
stem cell marker expression of different tumor cell lines might also be associated with 
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the specific tumor subtypes [139, 140]. In this regard, Olsson and coauthors [139] have 
shown that the expression of CD44 isoforms is mainly related to the HER2 status of the 
tumor and is stronger expressed in basal-like tumor subtypes. In the present thesis, 
however, it was not the aim to investigate the relation between CSCM expression and 
tumor subtypes, but to address the cellular consequences of CSCM expression in the 
context PI3K/Akt signaling and cellular radiation responses.  
As demonstrated downregulation of Akt1 exerted a stronger effect on the expression of 
the CSCM Nanog, Bmi1 and Sox2 as compared to downregulation of the Akt isoforms 
Akt2 and Akt3. The importance of Akt on CSCM expression is also demonstrated by a 
report of Gargini and coworkers [141], which indicated a significant reduction of sphere 
formation of CD44+/CD24- MDA-MB-231 breast cancer cells mainly after knock down 
of Akt1 when compared to knock down of Akt2.  
Likewise, in the present study the activity level of ALDH1 was altered, i.e. significantly 
reduced after knock out or knock down of Akt 1 and 3 isoforms in HBL-100 and 
HCT116. However, downregulation of Akt2 resulted only in HBL-100 cells in a 
significant reduction of ALDH activity, whereas in HCT116 only a marked but not 
significant reduction of ALDH activity could be demonstrated (Fig. 3.6). In line with 
these findings, it has been shown that overexpression of total cellular Akt and especially 
nuclear Akt leads to a stimulated ALDH activity and also increased Nanog as well as 
Oct-4 expression in SKBR3 and MDA-MB468 cells [142]. In addition, indirect 
inhibition of Akt using PI3K- or mTOR-inhibitors (B591 and rapamycin respectively) 
also showed a reduction of ALDH activity in breast cancer and osteosarcoma cells [143, 
144]. However, in these studies, the role of different Akt isoforms on ALDH activity 
was not investigated. Yet, for MCF-7 cells, knock down of the three Akt isoforms did 
not show a significant reduction of ALDH activity (Fig. 3.6). Likewise in regard to the 
present result, Vasudevan and coworkers [145] demonstrated that downregulation of 
three Akt isoforms did not affect tumor cell lines with PIK3CA mutation or with low 
level of p-AKT such as MCF-7, SW948 and HCT-15 either. Especially for the MCF-7 
cells analyzed in the present study, a low level of P-Akt was also to be observed. Thus, 
this might be the reason why knockdown of Akt isoforms did not regulate ALDH 
activity in MCF-7 cells. Due to very low amount of ALDH activity in MDA-MB-231 
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cells (appr. almost 0% ALDH activity), these cells could not be tested for the role of 
Akt isoforms on ALDH activity.   
 
4.2 Role of Akt and ALDH activity in radiation response of CSC in 
vitro 
 
Based on the importance of Akt on radiation response of tumor cells described in 
previous stuedies and reports by our laboratory [102, 104], the role Akt isoforms and 
ALDH activity was first tested on the clonogenic activity of irradiated breast cancer cell 
lines. These data study indicated that knockdown of Akt isoforms (Akt1, 2 and 3) leads 
to radio-sensitization of HBL-100 cells but not of MCF-7 cells. For MDA-MB-231 cells 
only knockdown of Akt3 resulted in radiosensitization (Fig. 3.8). These findings clearly 
indicate that Akt isoforms do affect the radiation response in a tumor cell type 
dependent manner. In this regard, it has previously been shown that Akt1 and Akt3 but 
not Akt2 via interaction with DNA-PKcs lead to a better DNA-DSB repair capacity and 
clonogenic activity in KRAS muted cells such as A549 and MDA-MB-231 [146]. 
Furthermore, Sahlberg and coworkers [147] demonstrated that knockdown of Akt1 and 
Akt2 results in radiosensitization of the colon cancer cells lines DLD-1 and HCT116. 
Accordingly, it has been demonstrated that knockout of both isoforms (Akt1 and 2) 
leads to radio-sensitization of DLD-1 and HCT116 tumor cells [147]; however in this 
report - due to a low expression level - the role of Akt3 in these cells was not 
investigated (147). Based on the data presented in this thesis (see Fig. 3.8), after 
knockdown of all three Akt isoforms the inhibition of ALDH activity with DEAB did 
not further affect the radiation response of the three tested cell lines HBL-100, MCF-7 
and MDA-MB-231. These results provide evidence that Akt functions upstream of 
ALDH and consequently knockdown depletion of Akt results in inhibition of ALDH. 
Accordingly, ALDH inhibition by DEAB treatment induces radiosensitization as it was 
shown herein for HBL-100 cells. This data is in line with findings by Krocer and 
coworkers [148], who have demonstrated that ALDH inhibition by DEAB or ATRA 
(all-trans retinoic acid) leads to radio and chemo-sensitization of CD44+/ALDH+ breast 
cancer cell lines.   
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The data of the present study demonstrating that inhibition or down regulation of 
ALDH1 affects differentially the radiation response of breast cancer cell lines are of 
special interest, since the used cell lines presented quite different radiation responses to 
DEAB treatment or siRNA mediated downregulation of ALDH1 (Fig. 3.3 and 3.5). 
Therefore, the percentage of ALDH activity in theses cell lines was analyzed. As it is 
shown in Fig. 3.5, HBL-100 cells with the highest ALDH activity were markedly 
stronger radiosensitized after inhibition of ALDH, as compared with the cell lines 
MDA-MB-231 and MCF-7 which presented the lowest ALDH activity. These findings 
indicate the importance and necessity of ALDH for the radiation response of these 
cancer cell lines. This assumption is also supported by data published by Charafe-
Jauffret and coworkers [149] and Marcato and coworkers [150] who demonstrated on 
the basis of 33 breast cancer cell lines presenting very low ALDH activity (0-1%, i.e. 
MCF-7 and MDA-MB-231) to very high ALDH activity that both, the metastatic 
potential as well as stem cell features clearly depend on the level of ALDH activity. 
With respect to the correlation of ALDH activity and cellular radiation response it needs 
also to be reflected that ALDH activity dependents not only on one isoform of ALDH 
but also on the isoforms such as ALDH1A1, ALDH1A3 and ALDH3 [151]. This 
assumption is supported by the report of Marcato and coworkers [150] who 
demonstrated that knockdown of ALDH1A3 in comparison to knockdown of 
ALDH1A1 results in a stronger suppression of ALDH activity in the three breast cancer 
cell lines MDA-MB-231, SKBR3 and MDA-MB-468. Moreover, Zhau and coworkers 
[152] investigated the role of 19 different ALDH isoforms on ALDH activity 
determined by the Aldefluor assay. This study indicated that nine out of nineteen ALDH 
isoforms are contributing to ALDH activity. These isoforms of ALDH were named by 
Zhau and coworkers as active ALDH isoforms [152]. In this report, based on 
endogenous mRNA profiles it could also demonstrate that MCF-7 breast cancer cells 
express primarily the isoform ALDH3A2 but not ALDH1 [152]. This result is in very 
good agreement with the data of ALDH activity determined in MCF-7 cells presented 
herein. In the context of the observation reported by Zhou and coworkers [152] it is of 
further interest, that DEAB does not inhibit the enzyme activity of all active ALDH 
isoforms (i.e. ALDH3B1 and ALDH5A1). Thus both, the report by Zhou and coworkers 
[152] as well as the data presented herein clearly indicate that the importance of specific 
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ALDH isoforms for the ALDH enzyme activity not only needs to be verify but also that 
more investigations are necessary in order to define a specific inhibitors of each active 
ALDH isoforms.  
 
4.3 Radiation response under 3D-culture condition  
 
A 3D-culture system is the gold standard method in in vitro stem cell research [153]. 
Thus, in the present study the sphere formation assay was applied to investigate breast 
cancer cell lines under 3D-culture condition. For these purposes, the breast cancer cell 
lines MCF-7, SKBR3 and MDA-MB-231 were applied.  A cell line specific time period 
for the formation of spheres was observed; likewise, the shape of spheres was 
dependent of the tumor cell line used. MCF-7 presented a round, SKBR3 a grape shape, 
and MDA-MB-231 a stellate sphere morphology (see Fig. 3.9). The data presented are 
in good agreement with data reported by Kenny and coworkers [154] who demonstrated 
a correlation of sphere morphology and gene expression for 25 breast cancer cell lines 
under 3D-culture condition. Four morphology characteristics, i.e. mass, round, grape-
like and satellite shapes were described by Kenny and coworkers (154). Interestingly, 
they also demonstrated that the cell lines with similar sphere shape morphology showed 
an equal gene expression pattern [154].   
Based on the clonogenic assay data under 3D-culture condition obtained in the present 
study, it is obvious that the plating efficacy of all breast cancer cell lines tested (in 
average less than 10 %) is markedly lower than that for the same cell lines under 2D-
condition. This effect is most likely to be explained by the fact that 3D-culture 
conditions provide a specific environment in which only CSCs can grow and form 
spheres. This is supported by previous reports indicating that depending on the tumor 
type the proportion of CSCs compared to tumor bulk cells is rather low [133, 155]. 
Moreover, Bahmad and coworkers [156] reported that the low plating efficiency under 
3D-culture is potentially also due to the strong tendency of formed neighboring spheres 
to merge in matrigel. Bodgi and coworkers [157] provided evidence that although the 
plating efficacy of the bladder cancer cell lines RT4 and UM-UC-3 is low under 3D-
culture condition, nevertheless the survival curves of these cells indicated a stimulated 
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and increased radioresistance of these cells both under 3D- and 2D-culture conditions. 
These authors postulated that the applied 3D-matrigel culture condition mediated the 
ability of these cells to survive even after exposure to high doses of ionizing radiation (8 
or 10 Gy) most likely due to the efficacy of matrigel to induce and stimulate cell 
proliferation after irradiation [157].   
Thus, the results on radioresistance of 3D-cultures of breast cancer cells presented 
herein are in good agreement with the previous literature report. The data of the present 
study even expand the mechanistic interpretation of the demonstrated cell- and 
radiobiological effects to the qualitative and quantitative level of CSC marker proteins. 
As it has been demonstrated in Fig. 11, ALDH activity of MCF-7 and MDA-MB-231 
cells is drastically increased under 3D-culture condition. Likewise, protein expression 
of the CSC markers Nanog and ALDH1 is elevated as well when cells are irradiated 
with a dose of 6 Gy. These findings together with the 3D-culture analyses indicate that 
mainly CSCs with high ALDH activity are able to form spheres under 3D-culture 
condition, whereas cells with low ALDH activity are rather limited in their ability to 
form spheres. These data also confirm the notion that sphere-culture systems indeed 
provide a suitable method for enrichment of CSCs populations.  
The presented data of this thesis are further in agreement with results reported by 
Lagadec and coworkers [158]. This group reported that irradiation (i.e. 4 and 8 Gy) 
stimulates ALDH activity of ALDH1-negative sorted SUM159PT breast cancer cells 
and additionally increases the percentage of CD24-/CD44+ cells in MCF-7 cultures  
[158]. Lagadec and coworkers [158] have also demonstrated that induction of CSCM 
such as Nanog, Oct-4 and Sox2 after irradiation is dependent on the dose of irradiation 
applied. Stimulated ALDH activity has further been reported by Reynolds and 
coworkers [159] for MDA-MB-231 under 3D- versus 2D-culture conditions. Likewise, 
gene expression of ALDH1A3, Sox2, Nanog and Oct4 increased markedly in spheroids 
when compared to 2D-cultured control cells [159]. In similar studies performed by 
Ghisolfi and coworkers [160] it was demonstrated that doses of 2 and 4 Gy but not 
higher doses (i.e. 6 and 8 Gy) of ionizing radiation did induce the expression of CSCM 
Sox2 and Oct-4 6 hours after radiation exposure and promoted sphere formation in 
hepatocellular carcinoma cells in vitro. Accordingly, knockdown of Sox2 and Oct4 
radiosensitized these cells and abrogated sphere formation [160].   
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4.4 Molecular radiobiological and differences of ALDH-positive and 
negative cells  
 
To address potential cell- and radiobiological differences in ALDH-positive and ALDH-
negative breast cancer cells, the ALDH-high expressing SKBR3 and HBL-100 cell lines 
were analyzed after sorting ALDH-positive and ALDH-negative subpopulations of 
these cell lines. The breast cancer cell lines MCF-7 and MDA-MB231 were excluded 
from the analyses due to the low levels of ALDH-activity expressed in these cells.  To 
avoid mixture of ALDH-positive and ALDH-negative subpopulations of the cell lines 
analysed, a specific distance between the gates of ALDH high and low cells has been 
introduced to ensure the purity of sorting. One reasons that originally strong ALDH-
positive cells loose the produced fluorescence signal is due to the increased level and 
presence of ATP-binding cassette transporters (ABC transporters). This was shown by 
Awad and coauthors [161] who demonstrated that Ewing’s sarcoma cells with high 
ALDH activity have more ABC transporter activity, which enables these cells to efflux 
chemotherapeutic drugs more efficiently. Accordingly, it has been shown that keeping 
cells on ice or at least at cool temperature slows down the activity of ABC transporters; 
thus, this methodology was used in the present study during cell sorting as well [162].   
The direct comparison of sorted ALDH-positive and ALDH-negative subpopulations of 
the applied breast cancer cell lines SKBR3 and HBL-100 cells indicated that only 
Nanog and Bmi-1 but not Oct4 and Sox2 are overexpressed in ALDH-positive cells 
(Fig. 12). In line with these data, it has been shown by Wu and coworkers [163] that 
ALDH-positive sorted cells from the gastric cancer cell lines MKN-45 and SGC-
7901could be characterized by an elevated expression of Nanog, Bmi-1 and Oct-4 when 
compared to ALDH-negative cells. Similar results were described by Awad and 
coworkers [161] based on q-PCR studies indicating that ALDH-positive but not ALDH-
negative Ewing’s sarcoma cells (TC-71) show elevated expression of Nanog, Bmi-1 and 
Oct-4. Likewise, reports by various groups [164-166] provided evidence that Sox2 [164, 
166], Bmi-1 [165] and Nanog [166] overexpression is apparent in side-population 
ALDH positive ovarian cancer cells, ALDH-positive head and neck (H&N) squamous 
cell carcinoma patient samples and in ALDH-positive melanoma cells. Thus, these 
literature data clearly indicate that ALDH-positive cells from different types of tumors 
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overexpress a variety of different stem cell markers. However, the fact that not all stem 
cell markers are equally overexpressed in different subpopulations of ALDH-positive 
tumor cell lines, may be indicative of a tumor type specificity.  
In this context, it needs to be discussed that also the specific expression of different 
ALDH-isoforms has importance. As shown herein, ALDH1A1 protein level was 
slightly overexpressed in ALDH positive HBL-100 cells but not in ALDH-positive 
SKBR3 cells. This data provided evidence for the assumption that different ALDH 
isoforms are of relevance for the ALDH-enzyme activity determined by the Aldefluor 
assay. To address this topic, the expression of ALDH1A3 was investigated in ALDH-
positive and ALDH-negative sorted subpopulations of the breast cancer cell lines HBL-
100 and SKBR3. The data received  indicate an upregulation of ALDH1A3 in ALDH-
positive cells of both HBL-100 and SKBR3 cells. Similar data were reported by Kurth 
and coworkers [167] indicating that ALDH1A3 is the main responsible isoform for 
ALDH activity in the H&N cancer cell lines FaDu and Cal33. Likewise, it has been 
reported by Marcato and coworkers [150] that mainly ALDH1A3 but not ALDH1A1 is 
responsible for ALDH activity in breast cancer cell lines such as MDA-MB-231, 
SKBR3 and MDA-MB-468. Thus, with respect to the importance of ALDH1A3, the 
data reported in the present study for breast cancer cell lines is in good agreement with 
the existing literature.  
Another important aspect of ALDH activity and its role and function in the context of 
the expression of other CSC markers relates to the activity level of the signaling 
component Akt. Akt has been described by our laboratory and others to be a main 
mediator of resistance of tumor cells to various forms of cancer treatments including 
radiation therapy [96]. Moreover, in the context of treatment resistance Mihatsch and 
coworkers [133] described previously that the radioresistance of ALDH-positive cancer 
cells in vitro can be antagonized by inhibitors of PI3K/Akt signaling. In the present 
study, it could be demonstrated that Akt activity as well as Notch protein expression is 
upregulated in ALDH-positive HBL-100 and SKBR3 cells. Similar data has been 
presented for ALDH positive murine osteosarcoma cells (K7M2) [168]. In these cells 
Notch signaling pathway components such as Notch1 and Hes1 are overexpressed and 
inhibition of Notch by DAPT treatment leads to reduction of ALDH activity [168]. In 
accordance with this data, it has also been reported [169, 170] that treatment with the 
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Notch inhibitor Psoralidin reduces ALDH activity of sorted ALDH-positive breast 
cancer cell lines as well as in ex vivo tumor samples from breast cancer patients. In the 
context of these data, it is of special importance that Psoralidin has also been identified 
to inhibit Akt activity in ALDH-positive cells via downregulation of Akt 
phosphorylation [169, 170]. 
By applying clonogenic survival assays as well as the determination of residual-γH2AX 
foci as indicator of DNA-DSB repair efficacy it could be demonstrated in the present 
study that ALDH-positive breast cancer cells are more resistant to ionizing radiation and 
present a stimulated DNA-DSB repair capacity (Fig. 3.13). These results are in line with 
previous reports demonstrating chemo- and radioresistance of ALDH-positive tumor 
cells in conventional 2D-culture systems [55-57, 133]. Similar results of radioresistance 
of ALDH-positive cells have been reported by Kurth and coworkers [167] for 3D-
cultures of the H&N cancer cell lines FaDu and Cal33. These authors [167] also 
observed less residual-γH2AX foci 24 and 48 h after irradiation of ALDH-positive cells 
when compared with ALDH-negative cells indicating a specific role of ALDH in DNA-
DSB repair [167]. Radioresistance and stimulated DNA-DSB repair efficacy via 
upregulation of P-Chk2 (Thr68) has also been shown for ALDH positive prostate cancer 
cells DU145 and PC53 [62]. Yet, neither in the studies described by Kurth and 
coworkers [167] nor by Cojoc and coworkers [62], the regulatory role of ALDH activity 
on different DNA-DSB repair pathways such as NHEJ and HR have investigated.  
4.5 Role of Nanog in DNA repair and ALDH activity 
 
For the present study and as already addressed in the context of various CSCM analyzed 
in strong ALDH positive breast cancer cells the protein Nanog was of special interest in 
the present study. This interest was based on the result that the expression of Nanog was 
clearly affected by ALDH activity of the cells tested. This was clearly demonstrated by 
the use of Nanog overexpression as well as downregulation using either a plasmid-
based overexpression or siRNA-based downregulation. The data received clearly 
indicated that Nanog promotes ALDH activity in MCF-7 and HBL-100 breast cancer 
cell lines (Fig. 3.14). In line with this finding, Jeter and coworkers [171] have also 
shown that Nanog overexpression stimulated ALDH activity in MCF-7 cells. This study 
was based on the use of a lentiviral transduction of the Nanog variants Nanogp8 and 
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Nanog1. Both variants induced ALDH activity and concomitantly led to upregulation of 
other CSCM, i.e. CD133 and CD44 [171].  
As shown in Fig. 3.15 of the present study downregulation of Nanog significantly 
impaired DNA-DSB repair and radiosensitized ALDH positive MCF-7 and HBL-100 
cells. Tanno and coauthors [172] have demonstrated that Nanog is highly overexpressed 
after irradiation (1Gy) of medulloblastoma bearing mice. In this study, it has also been 
shown that radiation-induced overexpression of Nanog promotes the selfrenewal 
capacity of GCPs (granule cell precursors), which can induce regrowth of 
medulloblastoma after irradiation [172]. Yet, a direct involvement of Nanog as a 
regulatory component DNA-DSB repair signaling was not investigated by Tanno and 
coworkers [172].  In the present study, however, this aspect was addressed in more 
detail. In this context, it has also been demonstrated by Cojoc and coworkers [62] that 
fractionated radiation induces the expression of Nanog and P-Akt in the prostate cancer 
cell line LNCaP. In contrast to the study by Cojoc and coworkers [62] and the study 
reported in the present thesis, Kim and coworkers [173] reported data indicating that the 
number of residual-γH2AX foci in Nanog-overexpressing mouse skin cells (K14-Na 
mouse model) is higher than in normal cells and that overexpression of Nanog in 293-
cells upregulates the phosphorylation of ATM and KRAB-associated protein 1 (Kap1). 
As a consequence these authors conclude that Nanog abrogates the DNA repair progress 
potentially via disturbance of Kap1 function. However, the contradiction of Kim and 
coworkers data [173] to the results presented in study herein as well as by Cojoc and 
coworkers [62] may be reflected in the interpretation of Nanog´s function in DNA-DSB 
repair. Thus, the different functions of Nanog in DNA repair might be due to potential 
differences between the cell types used or might be dependent on the time of evaluating 
residual-γH2AX foci. Yet and unfortunately, in contrast to the present study herein and 
the study by Cojoc and coworkers [62] the report by Kim and coworkers [173] does not 
indicate the exact evaluation time of residual-γH2AX foci after irradiation.  
To fulfill its regulatory function on various cellular processes Nanog needs to be 
translocated to the nucleus [70]. Based on the data present in this thesis, Nanog 
translocates to the nucleus in a time dependent manner both, after irradiation as well as 
ligand activation of EGFR (Fig. 16, 17). Do and coauthors [174] demonstrated by 
applying mutations in different domains of Nanog (N-terminal, Homeodomain and C-
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terminal) in the kidney fibroblast cell line COS-7 c that the nuclear localization signal 
(NLS) motif is located in the homeodomain of Nanog and is essential for nuclear 
translocation. Bourguignon and coworkers [34] reported that CD44 stimulation by 
hyaluronan treatment promotes nuclear translocation of Nanog in complex with Oct-4 
and Sox2 in tumor-derived HSC-3 cells presenting CD44 high/ALDH1 high. As 
described [34] nuclear translocation of the Oct4/Sox2/Nanog complex leads to 
upregulation of miR302 expression, which induces selfrenewal and chemoresistance of 
CD44 high/ALDH high HSC-3 cells. In this context it is of interest that in the present 
thesis, it could be demonstrated that inhibition of PI3K/Akt signaling abrogates post-
irradiation nuclear translocation of Nanog (Fig. 3.18). In line with this data, it has been 
shown that EGF treatment drastically stimulates nuclear localization of Nanog and 
nuclear translocation of β-catenin in the lung cancer cell lines A549 and H23 [175]. 
Furthermore, and in line with the results presented herein, evidence was provided that 
inhibition of EGFR signaling by the tyrosine kinase inhibitor gefitinib and inhibition of 
PI3K/Akt pathway by the kinase inhibitor LY294002 results in downregulation of 
Nanog and nuclear level of β-catenin in nasopharyngeal carcinoma CNE2 cells [176]. 
So far however, neither the critical level of nuclear Nanog needed for its specific role 
nor the role of irradiation or EGFR signaling pathway on nuclear translocation of Nanog 
has been described in the literature. Especially against this background, the correlation 
of nuclear translocation of Nanog and radiation response needs to be investigated 
further.  
4.6 Functional role of Nanog for expression of Notch1 and Akt 
activity  
 
In the context of potential signaling interactions of Akt, Notch and Nanog, which may 
regulate radiation responses of breast cancer cells, specifically the role of Notch and Akt 
proteins for Nanog expression was analyzed.  To this aspect, Noh and coworkers [177] 
have shown that downregulation of Nanog in the cervical cancer cell line Caski, leads to 
inhibition of P-Akt whereas overexpression of Nanog strongly induces P-Akt level in 
these cells. Moreover, inhibition of Akt activity by using API2 treatment abrogated 
sphere formation and apoptosis of immune selected Nanog overexpressing Caski cells 
[177]. Thus, in the present study the signaling pathways through which Nanog may 
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regulate both ALDH activity and radiation response of breast cancer cells were 
investigated. By various approaches, it could be demonstrated that overexpression as 
well as downregulation of Nanog can modulate Akt activity and Notch expression (Fig. 
3.19). These results indicate that Nanog functions as upstream component of Akt and 
Notch expression. However, based on data reported by Chang and coauthors [92] 
showing that dual targeting of Akt and mTOR with BEZ235 downregulates CSCM 
expression and especially that of Nanog in the prostate cancer cell lines. Chang and 
coworkers [92] also demonstrated that the combination of BEZ235 with radiation (6 
Gy) efficiently reduced colony formation of radioresistant prostate cancer cells. Thus, 
these results do indicate that Akt can function upstream of Nanog. Additional reports 
[178, 179] demonstrated that Notch inhibition can lead to downregulation of Nanog and 
Sox2; these results thus indicate that Notch can regulate Nanog.  
Yet, the data shown in Fig. 3.21 of the present thesis indicated that downregulation of 
Notch and Akt results in radiosensitization of Nanog overexpressing cells. In line with 
this data, it has been shown that knockout of Notch in glioblastoma cells (i.e. U87MG 
and U251) mediates an impaired DNA-DSB repair [130]. Similarly, in a further study 
by Wang and coworkers [127], it has been demonstrated that Notch inhibition by GSI 
(gamma secretase inhibitor) in combination with radiation exposure results in an 
impaired clonogenic cell survival and induction of caspase 3/7 activity in CD133+ 
glioma stem cells, which suggests stimulation of radiation induced apoptosis. Moreover, 
these data also demonstrate that Notch via regulating Akt activity promotes 
radioresistance in CD133+ glioblastoma cells [127] (see summary figure).  
In the context of upregulated ALDH activity in Nanog overexpressing cells, the 
potential signaling interactions of Akt, Notch and Nanog were also analyzed in the 
present thesis. It could be demonstrated that Nanog via Akt and Notch signaling induces 
ALDH activity (Fig. 20). To this aspect, Zhao and coworkers [66] have shown that 
Notch via Sirt2 stimulates deacetylation of ALDH1, which leads to the induction of 
ALDH1 enzyme activity in the MDA-MB-468 breast cancer cell line. In addition, 
Notch inhibition by DAPT (N-[N-(3,5-difluorophenacetyl)- L-alanyl]-S-phenylglycine 
t-butyl ester) treatment reduces more than 50% of ALDH activity in MDA-MB-468 
[66]. Accordingly, it has been reported [180], that inhibition of the PI3K/Akt pathway 
by LY29004 treatment reduces ALDH activity in multidrug-resistance derived breast 
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cancer cell lines MCF-7/A02 and CALDOX. Based on these reports to the topic and the 
data presented in the thesis it can be concluded as demonstrated in the summary figure 
below that Nanog via regulating Akt and Notch signaling promotes ALDH activity in 
tumor cells.  
 
Summary Figure: schematic summary of the potential regulatory mechanisms based on the 
data presented in the current thesis. The written figure numbers on each arrow refers to the 
related data in the result section 3.  
 
4.7 Conclusion and Outlook 
 
Based on the presented data of this thesis, it can be concluded that ALDH inhibition 
with specific siRNA or DEAB treatment differentially affects the radiation response of 
different breast cancer cell lines. This finding might be due to the dependency of cells to 
ALDH activity and the basal level of ALDH expression and activity in the different cell 
lines analyzed. Moreover, downregulation of the Akt isoforms Akt1, Akt2 and Akt3 
leads to reduction of ALDH activity in HBL-100 and HCT116 cells but not MCF-7 
cells. The non-responsiveness of MCF-7 cells is most likely due to the independency of 
MCF-7 cells to PI3K/Akt signaling based on described PIK3CA mutation. Similarly, 
knockdown of the Akt isoforms Akt1, Akt2 and Akt3 did not alter the radiation 
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response of MCF-7 cells. However, downregulation of these Akt isoforms 
radiosensitized HBL-100 cells and additional inhibition of ALDH by DEAB treatment 
did not lead to a further radiosensitization in these knockdown cells. This finding 
indicates that Akt functions upstream of ALDH in radiation response. The comparison 
of low plating efficiencies under 3D-culture vs. high plating efficiencies under 2D-
cultures, indicates that the minority of cells in a given tumor cell population in vitro 
represents CSCs.  
In ALDH-positive cells, the expression of Nanog, Bmi1, P-Akt and Notch is markedly 
upregulated and ALDH-positive cells show a significantly enhanced DNA-DSB repair 
capacity as well as improved clonogenic cell survival. Downregulation of Nanog 
abrogated DNA-DSB repair efficacy and radiosensitized ALDH-positive cells. This 
finding indicates that the cellular radiation response of ALDH-positive cells is clearly 
dependent on the expression of Nanog. Furthermore, western blot data confirmed that 
Nanog regulates Notch expression as well as Akt activity. Inhibition of Akt and Notch 
prevented the modulatory effect of Nanog on the induction of ALDH activity and 
cellular radiation response. Thus, it can be concluded that high ALDH activity induces 
radioresistance of tumor cells via overexpression of Nanog and interacting pathways 
such as Akt and Notch summarized in summary figure.  
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5 Summary  
 
Radiation therapy is applied alone or in combination with surgery and/or chemotherapy 
for therapy of most solid tumors. However, despite many advances in radiation 
oncology, radioresistance and cancer recurrence are still major problems. There are 
various mechanisms, which trigger radioresistance and tumor relapse and cancer stem 
cells (CSCs) have been identified as the major cause of radioresistance. Several 
mechanisms are described in CSCs to mediate radioresistance including stimulated 
DNA repair, hyperactivated survival pathways, like the PI3K/Akt as well as expression 
and stimulated activity of the CSC marker protein ALDH. As of yet, the precise 
mechanisms of how the CSC marker ALDH triggers therapy resistance are not fully 
understood. In the present study, the role of PI3K/Akt pathway and other CSC markers 
in the regulation of ALDH activity and radiation response of human cancer cell lines in 
vitro was investigated.  
By the use of FACS-selected highly ALDH-positive subpopulations of breast cancer 
cell lines in vitro, it could be demonstrated that ALDH-positive cancer cells presented a 
significantly elevated radioresistance profile when compared to ALDH-negative 
subpopulations. Knockdown of Akt isoforms, Akt1, Akt2, and Akt3 led to 
downregulated ALDH activity in HBL-100 and HCT116 cancer cells. Yet, 
downregulation of Akt isoforms mediated radiosensitization of HBL-100 but not of 
MCF-7 breast cancer cells and inhibition of ALDH activity with DEAB treatment did 
not show any additional effect on post-irradiation cell survival after knockdown of Akt 
isoforms.  
Assessing the protein expression profile of ALDH-positive cells revealed an 
upregulation of the stem cell markers Nanog, Bmi1 and Notch proteins as well 
stimulated P-Akt levels when compared to ALDH negative cells.  In line with these data 
it could be demonstrated that ALDH-positive and radioresistant in contrast to ALDH-
negative and radiosensitive cancer cells presented a stimulated DNA-DSB repair 
capacity. Moreover, knockdown of Nanog in ALDH-positive cancer cells resulted in an 
abrogation of the stimulated DNA-DSB repair capacity and consequently in a 
radiosensitization when compared to control cells.  Additionally, knockdown of Nanog 
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led to downregulation of Notch expression and Akt activity. In line with this data, 
inhibition of Notch and Akt activity resulted in abrogation of stimulated post-irradiation 
cell survival as well as ALDH activity in Nanog overexpressing cancer cells. Further 
and most interestingly, it could be observed that nuclear translocation of Nanog is 
stimulated in a time dependent manner after radiation exposure of cancer cells. 
Accordingly, Nanog knockout DU145 cells present an impaired DNA-DSB repair and 
are more radiosensitive than Nanog expressing parental cells. These data confirmed the 
results obtained from Nanog knock down cells and thus supported the conclusion 
concerning the role of Nanog in post radiation response of cancer cells. 
Altogether, the results presented in this study provide evidence that the high expression 
of ALDH in potential breast cancer stem cells is a consequence of upregulation of 
Nanog and Notch protein expression as well as stimulated Akt activity, which results in 
an improved DNA-DSB repair capacity. Compared to breast cancer cells with low 
ALDH activity these molecular alterations most likely result in the observed 
radioresistant phenotype of ALDH-positive breast cancer cells. 
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6 Zusammenfassung 
 
Die Strahlentherapie wird allein oder in Kombination mit einer Operation und / oder 
Chemotherapie für die Behandlung der meisten soliden Tumoren angewendet. Trotz 
vieler Fortschritte der Radioonkologie bilden die Strahlenresistenz von Tumoren unter 
und das Wiederauftreten von Krebs nach erfolgter Therapie nach wie vor große 
Probleme. Es gibt verschiedene zelluläre und molekulare Mechanismen, die 
Strahlenresistenz sowie das Wiederauftreten eines Tumors auslösen können. In den 
letzten Jahren konnten Krebsstammzellen (CSCs) als Hauptursache für die 
Strahlenresistenz identifiziert werden. Für CSCs wurden verschiedene Mechanismen 
zur Vermittlung der Strahlenresistenz beschrieben, darunter eine stimulierte DNA-
Reparatur, hyperaktivierte Überlebenswege wie PI3K / Akt sowie die Expression und 
stimulierte Aktivität des CSC-Markerproteins ALDH. Die genauen Mechanismen, wie 
der CSC-Marker ALDH Therapieresistenz auslöst, sind allerdings noch nicht 
vollständig geklärt. In der vorliegenden Studie wurde die Rolle des PI3K / Akt-
Signalwegs und anderer CSC-Marker bei der Regulation der ALDH-Aktivität und der 
Strahlungsantwort von menschlichen Krebszelllinien in vitro untersucht. 
Durch die Verwendung von FACS-selektierten hoch ALDH-positiven Subpopulationen 
von Brustkrebszelllinien in vitro konnte gezeigt werden, dass ALDH-positive im 
Vergleich zu ALDH-negativen Subpopulationen ein signifikant erhöhtes 
Strahlenresistenzprofil aufweisen. Knock-down der drei Akt-Isoformen Akt1, Akt2 und 
Akt3 führte zu einer Herunterregulation der ALDH-Aktivität sowohl in HBL-100- als 
auch in HCT116-Krebszellen. Eine Herunterregulierung von Akt-Isoformen vermittelte 
eine starke Radiosensibilisierung beiHBL-100- jedoch nicht bei MCF-7-
Brustkrebszellen; eine Hemmung der ALDH-Aktivität durch Behandlung mit DEAB 
zeigte jedoch keinen zusätzlichen Effekt auf das Zellüberleben nach Bestrahlung im 
Kontext herunterregulierter Akt-Isoformen. 
Die Analyse des Proteinexpressionsprofils von ALDH-positiven Zellen ergab im 
Vergleich zu ALDH-negativen Zellen eine Hochregulation der Stammzellmarker 
Nanog, Bmi1 und Notch sowie einen stimulierten P-Akt-Spiegel. In Übereinstimmung 
mit diesen Daten konnte gezeigt werden, dass ALDH-positive und strahlenresistente 
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ALDH-positive Krebszellen im Gegensatz zu ALDH-negativen und 
strahlenempfindlichen Zellen eine stimulierte DNA-DSB-Reparaturkapazität aufweisen. 
Darüber hinaus führte der Unterdrückung von Nanog in ALDH-positiven Krebszellen 
zu einer Aufhebung der stimulierten DNA-DSB-Reparaturkapazität und damit zu einer 
Radiosensitivierung. Zusätzlich resultierte die Herunterregulation der Nanog-
Expression in einer verringerten Notch-Expression sowie reduzierter Akt-Aktivität. In 
Übereinstimmung mit diesen Daten kam es durch Hemmung der Notch- und Akt-
Aktivität zur Aufhebung des signifikant verbesserten Zellüberlebens nach Bestrahlung 
sowie einer Unterdrückung der ALDH-Aktivität in Nanog-überexpri-mierenden 
Krebszellen. Weiterhin konnte interessanter Weise beobachtet werden, dass nach 
Strahlenexposition die nukleare Translokation von Nanog zeitabhängig stimuliert wird. 
Dementsprechend weisen Nanog-Knockout-DU145-Zellen eine beeinträchtigte DNA-
DSB-Reparatur auf und sind signifikant strahlenempfindlicher als Nanog-exprimierende 
Parentalzellen. Diese Daten bestätigten die Ergebnisse an Nanog-Knock-down-Zellen 
und stützten somit die Schlussfolgerung bezüglich einer wichtigen Rolle von Nanog bei 
der zellulären Strahlenreaktion von Krebszellen. 
Insgesamt zeigen die in dieser Studie vorgestellten Ergebnisse, dass die hohe 
Expression von ALDH in Brustkrebszellen eine Folge der Hochregulation der Nanog- 
und Notch-Proteinexpression sowie einer stimulierten Akt-Aktivität ist. Dieses 
Zusammenspiel führt zu einer verbesserten DNA-DSB-Reparaturkapazität. Im 
Vergleich zu Brustkrebszellen mit niedriger ALDH-Aktivität führen diese molekularen 
Veränderungen höchstwahrscheinlich zu dem beobachteten strahlenresistenten 
Phänotyp von ALDH-positiven Brustkrebszellen. 
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